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J. Alex Washburn 
 
EXPLORING DUAL-TARGETING GROEL/ES & PTPB INHIBITORS AS A NEW 
ANTIBIOTIC STRATEGY FOR TUBERCULOSIS 
 
Current Mycobacterium tuberculosis (Mtb) treatments suffer from an increase in 
antibiotic resistance strains and the lack of efficacy against latent state tuberculosis, thus 
novel approaches targeting different mechanisms of action are needed. One strategy to 
target Mtb is to target protein homeostasis pathways by inhibiting molecular chaperones, 
in particular, GroEL/ES (HSP60/10) chaperonin systems. Mtb has two homologs of 
GroEL, of which GroEL1 is not essential, but is important for cytokine-dependent 
granuloma formation, and GroEL2 is essential for survival and the likely canonical 
housekeeping chaperonin. Another strategy to target Mtb is to target the protein tyrosine 
phosphatase B (PtpB) virulence factor that Mtb secretes into host cells to help evade 
immune responses. Thus, we envisioned that this analog series might also be capable of 
inhibiting Mtb PtpB along with GroEL. By developing compound 1 inhibitors that could 
act on all of GroEL1, GroEL2, and PtpB, we could have an antibiotic candidate that 
targets all stages of tuberculosis: actively replicating bacteria, bacteria evading host cell 
immune response, and granuloma formation in latent disease. 
In the Johnson lab, previous studies explored GroEL/ES inhibitors, with 
compound 1 being one of the most potent inhibitors, inhibiting both Trypanosoma brucei 
and Staphylococcus aureus proliferation. In the present study, we have screened 
previously developed compound 1 analogs, as well as a series of newly synthesized 
analogs that we term “half-molecules”. In this study, our results indicated two potential 
avenues to explore for future research. The first is a series of carboxyl-bearing 
compound 1 inhibitors, compounds 2m-o, 2m-m, and 2m-p, which act solely on Mtb 
PtpB phosphatase activity without inhibiting GroEL. The second is a series of compound 
1 inhibitors (e.g. 20R and 20L) that are able to inhibit both the PtpB phosphatase and 
	vi 
GroEL/ES chaperonin system. Thus, this exploratory study showed the possibility of 
pursuing such a polypharmacological antibiotic strategy against Mtb infections and with 
further optimization, such dual-targeting GroEL/ES and PtpB inhibitors could be effective 
against all stages of tuberculosis. 
 
Steven M. Johnson, Ph.D., Chair 
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INTRODUCTION 
Mycobacterium tuberculosis stages and implications. 
 Tuberculosis is a serious bacterial infectious disease that has beset people over 
the course of human history. Mycobacterium tuberculosis (Mtb), the causative agent  
of tuberculosis, has survived for over 70,000 years with the Mycobacterium genus 
originating more than 150 million years ago (Barberis 2017). Tuberculosis rates and 
deaths soared during the 19th century, prompting physicians and scientists to try to 
understand the etiology of the disease. It wasn’t until the late 19th century, when Robert 
Koch isolated the tubercle bacillus and put forward his famous postulates about 
infectious etiology, that scientists could understand how tuberculosis is contracted 
(Daniel 2006). Mtb infects around 1 in 4 people, or about 2 billion people worldwide 
(CDC Features 2018). In 2016, over 10 million active cases of tuberculosis infection 
were reported with 1.7 million deaths attributed to the deadly disease. Countries with 
poorer access to healthcare and socioeconomic problems are affected more and hit 
harder with cases of tuberculosis, as outlined in Figure 1 (Tuberculosis 2018).  
Mtb is a facultative intracellular bacterium that is neither Gram-positive nor Gram-
negative, but instead is coated in a fatty, mycolic acid outer wall. Mtb is transmitted as 
an airborne particulate generated when people with active tuberculosis cough or sneeze 
(Jackson 2016). When inhaled, the infectious bacteria traverse the respiratory tract to 
the alveoli where they infect phagocytic cells, namely macrophages. Mtb has adapted to 
endure a diverse set of microenvironments in the host. Each unique microenvironment, 
along with host immune effectors, encourages Mtb to exist in either an active or latent 
state (Pai 2016, Lupoli 2018). Mtb are a slow replicating bacterium with doubling rates 
between 18-54 h (Gill 2009). Initially, infection with Mtb is believed to occur in alveolar 
macrophages (Flynn 2001). The bacteria replicate within macrophages and induce 
cytokines that initiate the inflammatory response in the lungs. Macrophages and 
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lymphocytes migrate to the site of infection and form a granuloma. Latent TB is 
essentially where there is equilibrium between the host and bacillus. During this state is 
where the host prevents the disease from becoming active while the bacterium avoids 
elimination (Flynn 2001). Latent TB in a granuloma state can persist for years without 
producing any symptoms (Figure 2). In around 90% of all TB infections, the immune 
response is sufficient to keep the disease in a latent state (Flynn 2001). However, a 
weakened immune system can lead to re-activation of dormant Mtb from the 
granulomas. Active TB spreads and proliferates to other macrophages in the body, 
having mild to severe symptoms depending on the severity of the disease (Figure 2). If 
left untreated, tuberculosis can affect other body organs and functions, which can 
ultimately become fatal (Smith 2003).  
 
Figure 1 – Estimated global TB incidence per 100,000 people. Tuberculosis is 
proportional to access to healthcare and socioeconomic problems. Southeast Asia and 
southern Africa have the highest cases of tuberculosis per population. (Figure adapted 
from Pai 2016). 
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Figure 2 – Different stages of tuberculosis with symptoms and treatments. Bacterial 
infection can be eliminated but if not, can be present at multiple TB phases. Latent TB 
has bacteria evading host cell immune response by hiding in macrophages and forming 
a granuloma. Latent TB produce no symptoms, so diagnosis and treatment are difficult. 
Latent TB can become active which spread to and infect other cells. Active TB has 
actively replicating bacteria spreading to other cells in the body. Symptoms for active TB 
can be mild to severe with multidrug therapy required for treatment. (Figure from Pai 
2016). 
 
Current tuberculosis treatments. 
Current efforts to abate tuberculosis include vaccinations for prevention and 
antibiotics for treatment. The only available vaccination for Mtb is Bacille Calmette-
Guérin (BCG) and its efficacy varies for patients. The efficacy depends on the variability 
and virulence of the disease (Vaudry 2003). BCG is not administered in the United 
States and is generally only given to children in countries with a high TB prevalence. 
BCG does prevent some serious TB complications, such as meningitis, but fails to 
effectively protect children from TB-related pulmonary disease, to prevent latent infection 
from progressing to active disease, and to prevent the spread of the disease (Luca 
2013). Furthermore, the vaccine is not used much in adults because of their lower risk of 
infection as well as the variable effectiveness of the vaccine against adult pulmonary TB 
(Luca 2013). Because of the inefficacy of TB vaccinations, antibiotic drugs have been 
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the primary method for countering Mtb infections. Typical first-line antibiotics include 
isoniazid, rifampin, ethambutol, and pyrazinamide (Table 1), which function by targeting 
cell wall synthesis as well as protein synthesis (Treatment of Tuberculosis 2010). 
Because of their mechanisms of action, compounds are primarily successful against 
actively replicating bacteria; however, since Mtb replicates so slowly, combination 
therapy is typically administered for at least six-to-nine months to completely eliminate 
the bacteria. This extensive treatment often leads to patient non-compliance 
(Tuberculosis 2018). When patients neglect to finish the full extent of their treatments, 
the mycobacteria colonies can become resistant to antibiotics and persist, leading to 
increasing resistance to first-line antibiotics. Multi-drug resistant tuberculosis requires 
more potent second-line antibiotics such as fluoroquinolones and injectable second-line 
drugs such as kanamycin in combination with first-line antibiotics (CDC Features 2018). 
Extensively-drug resistant Mtb are resistant to first-line drugs as well as second-line 
antibiotics used to treat multi-drug resistant tuberculosis. Antibiotics used to treat 
extensively-drug resistant tuberculosis include the recently approved drugs bedaquiline 
and delamanid, which target and block ATP synthase and mycolic acid biosynthesis in 
mycobacteria (D’Ambrosio 2017). Furthermore, Mtb colonies can persist in lung tissue in 
the latent phase, which often evades medical notice and makes proper diagnosis of the 
disease increasingly difficult. If diagnosed, first-line antibiotics such as rifampicin and 
isoniazid can be used to prevent the bacteria from becoming active, but many of the 
active tuberculosis antibiotics used are ineffective against latent-phase infection 
(Houston 2002). Accordingly, while vaccines and treatments are available, their efficacy 
is mixed, in particular because incidences of multi-drug and extensively-drug resistant 
strains are rising. 
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Table 1 – Information on current tuberculosis antibiotics on the market (Butler 2016). 
 
Example Therapy 
Use 
Date Introduced Mechanism of Action 
Isoniazid 
 
First-line 1952 Inhibits synthesis of 
mycolic acids 
Rifampicin 
 
First-line 1966 Inhibits RNA polymerase 
Ethambutol 
 
First-line 1961 Inhibits arabinosyl 
transferase, involved in 
cell wall biosynthesis 
Pyrazinamide 
 
First-line 1952 Inhibits fatty acid synthase 
Bedaquiline 
 
Second-line 2012 Inhibits ATP proton pump 
Delamanid 
 
Second-line 2014 Inhibits mycolic acid 
biosynthesis 
           
A new antibacterial strategy: targeting bacterial GroEL/ES chaperonin systems to 
disrupt protein folding. 
With current medical efforts to combat tuberculosis becoming increasingly 
ineffective, it is necessary to develop novel approaches targeting different mechanisms 
of action to overcome multi-drug resistance. One such strategy that we are exploring is 
targeting bacterial protein homeostasis pathways. A network of molecular chaperones 
and proteases collectively functions to maintain protein homeostasis by assisting 
proteins to fold to their native, functional states, or ensuring their proper degradation 
N
H
NO NH2
N
H
H
N
OH
HO
N
N NH2
O
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(Chapman 2006, Xu 1998). Since many molecular chaperones, which are also known as 
Heat Shock Proteins (HSPs), are essential under normal and stress conditions, targeting 
them with small molecule inhibitors should be an effective antibacterial strategy. E. coli 
GroEL, which is the prototypical member of the HSP60 chaperonin family, is a homo-
tetradecameric protein that forms two, seven-subunit rings that stack back-to-back with 
one another (Figure 3). Through a series of events driven by ATP binding and hydrolysis 
(Figure 4), unfolded substrate polypeptides are bound within the central cavity of a 
GroEL ring and are encapsulated by the GroES co-chaperonin lid, allowing protein 
folding within the sequestered chamber (Horwich 2006). 
 
 
Figure 3 – GroEL/ES chaperonin structure. GroEL is as a homo-tetradecameric complex 
consisting of two, seven-subunit rings stacked back-to-back. To facilitate polypeptide 
folding, the 7-subunit GroES “lid” caps off the GroEL rings, where unfolded polypeptides 
are encapsulated and allowed to fold to their native states (schematic of the polypeptide 
folding cycle is shown in Figure 4). Images are adapted from the 4V43 and 1SX4 crystal 
structures (Chaudhry 2004). 
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Figure 4 – Schematic of the GroEL/ES-mediated folding cycle. 1. Unfolded polypeptide 
binds to the GroEL apical domains, with ATP binding to the equatorial domains (seven 
ATPs bind per GroEL ring). 2. GroES binds to the GroEL apical domains and releases 
the unfolded polypeptide into the GroEL cis-cavity, where folding occurs. 3. ATP 
hydrolysis releases the negative cooperativity to the GroEL trans-ring. 4. ATP and 
another unfolded polypeptide bind to the GroEL trans-ring, signaling ejection of cargo 
from the initial cis-ring. The folding cycle then continues in the new cis-ring (Horwich 
2006). 
 
Mtb has two homologs of GroEL – GroEL1 and GroEL2. GroEL2 is an essential 
gene for the survival of Mtb and if knocked out, Mtb fails to grow (Hu 2008). Thus, 
targeting GroEL2 with small molecule inhibitors should be an effective strategy to kill 
mycobacteria. While GroEL1 is not essential, it is important in regulating cytokine-
dependent granuloma formation (Hu 2008). When infected with GroEL1-deficient 
(∆cpn60.1) mutant Mtb, both mice and guinea pigs produced equal number of bacteria 
as the WT-GroEL1; however, the mutant strain failed to produce granulomatous 
inflammation. Thus, targeting GroEL1 with small molecule inhibitors could also thwart 
granuloma formation. These enticing findings suggest that inhibitors that act on both of 
the Mtb GroEL homologs could treat both the active and latent stages of tuberculosis. 
Previous studies identifying GroEL/ES inhibitors for hit-to-lead development as 
antibiotic candidates. 
Towards our goal of exploiting HSP60/10 and GroEL/ES chaperonin systems as 
an antibiotic strategy, we previously reported a high-throughput screen for small 
ATP	 ATP	
	
ATP	 ATP	
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ATP	
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ATP	
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molecule inhibitors of the E. coli GroEL/ES chaperonin system (Johnson 2014). A 
schematic of the general GroEL/ES-mediated folding assay protocol is outlined in Figure 
5. In general, a denatured reporter enzyme - we typically use malate dehydrogenase 
(MDH) or rhodanese (Rho) for our compound evaluations - is mixed to create a binary 
complex with GroEL. GroES and ATP are then added to initiate the folding cycle. After 
adequate incubation time to allow proper folding of the reporter enzyme, the amount of 
enzymatic activity by the refolded reporter enzyme is monitored by the addition of an 
enzyme assay solution. Using this general assay protocol, 235 GroEL inhibitors were 
identified by screening against a library of 700,000 molecules (Johnson 2014). In a 
subsequent study, we evaluated 22 of these GroEL/ES inhibitor hits for their antibacterial 
properties against bacteria termed the ESKAPE pathogens - an acronym that stands for 
Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter species. While ineffective 
against each of the bacterial species, these studies identified compound 1 (Figure 6) as 
one of the most potent inhibitors of both the refolding and ATPase functions of GroEL 
(Abdeen 2016). 
A PubChem database search found a related compound 1 analog (the 2-
phenylbenzoxazole 2e-p) that elicited antimicrobial functions against Leishmania major 
promastigotes while being reported active in only 8 out of 285 bioassays, showing 
inherent selectivity. Thus, in a follow up study, we evaluated a series of compound 1-
based GroEL/ES inhibitors for their antibiotic effects against a related parasite, 
Trypanosoma brucei, which are the causative agent of African sleeping sickness 
(Abdeen 2016). In an extension of those studies, we explored asymmetric compound 1 
analogs for their antibiotic effects against the ESKAPE pathogens. In that study, while 
we found that inhibitors were largely ineffective against Gram-negative bacteria, many 
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exhibited potent inhibition of the proliferation of Gram-positive bacteria, in particular 
Staphylococcus aureus (Abdeen 2018). 
   
Figure 5 – Schematic of the general GroEL/ES-mediated folding assays used for 
evaluating test compounds. A. Compounds are added to a binary mixture of GroEL, 
GroES, and unfolded enzyme reporter. ATP is added to initiate the folding cycle, and 
after a short incubation time (30-60 min, depending on the particular enzyme to be 
folded), EDTA is added to quench the cycle (in the case of rhodanese as the reporter 
enzyme, no EDTA quench is added). Inhibitors are added at point A for the refolding 
assay plate while inhibitors are added at point B for the native counter-screen plate. This 
was done to determine if compounds inhibit native enzyme reporter activity instead of 
GroEL/ES. Reporter substrates are added to determine the activity of the reporter 
enzyme and thus the efficacy of the refolding mechanism (Johnson 2014). The 
enzymatic reporter reactions are shown for malate dehydrogenase (panel B) and 
rhodanese (panel C). 
 
With our compound 1 analogs eliciting antibiotic effects against parasites and 
bacteria, and because GroEL is highly conserved across all organisms (Table 2), we 
reasoned that they may also exhibit antibiotic effects against M. tuberculosis. Thus, in 
the present study, we evaluated the previously developed compound 1 analogs for their 
ability to inhibit M. tuberculosis proliferation in liquid media. Because we were unsure 
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whether or not these compounds required both of the sulfonamide end-capping groups 
to maintain potent inhibition, we developed a new series of what we term “half-
molecules” that contain only one sulfonamide on either the right or left-hand sides of the 
2-phenylbenzoxazole core (Figure 6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6 – Summary of progression of compound 1 testing and optimization from 
previous studies. i. Compound 1 was an initial hit that emerged from our recent high-
throughput screening for GroEL/ES inhibitors (Abdeen 2016). ii. The related analog, 2e-
p, was found in the PubChem database (CID #1098316) and had reported bioactivity in 
only 8 of the 285 assays it has been evaluated in. Analog inhibitors were found to be 
cytotoxic to Trypanosoma brucei parasites. In this study, 50 inhibitor analogs bearing 
this scaffold were tested. iii. Asymmetric compound 1 inhibitor analogs with both left and 
right-hand series were tested on the ESKAPE pathogens. Inhibitors were found to be 
cytotoxic to Gram-positive bacteria. In that study, 40 inhibitor analogs bearing this 
scaffold were tested. iv. Half-molecule compound 1 inhibitor analogs with both the left 
and right-hand series. The current study will look into the efficacy of these inhibitors. In 
this study, 58 inhibitor analogs bearing this scaffold were tested. Representative 
substituents in the R position for the inhibitor analogs are presented. 
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Table 2 – Conservation between GroEL (HSP60) chaperonins. Values represent % 
identical amino acids compared to E. coli GroEL. 
 
Species GroEL (HSP60) 
E. coli 100% 
S. aureus 57% 
T. brucei (HSP60.1) 53% 
T. brucei (HSP60.2) 43% 
T. brucei (HSP60.3) 40% 
M. tuberculosis (GroEL1) 54% 
M. tuberculosis (GroEL2) 59% 
 
Exploring the ability of compound 1 analogs to also inhibit Mtb protein tyrosine 
phosphatase B (PtpB), which could allow the targeting of intracellular bacteria 
evading host cell immune responses. 
Another possible strategy to treat tuberculosis infections is by targeting a 
virulence factor that Mtb secretes into the cytoplasm of host macrophages, protein 
tyrosine phosphatase B (PtpB). By secreting PtpB into the cytosol of host macrophages, 
Mtb disrupts host cell immune responses by blocking ERK1/2 and p38 mediated IL-6 
production and promoting host cell survival by acting on the Akt pathway (Zhou 2010). 
Deletion of PtpB has been shown to block intracellular survival of Mtb in IFN-𝛾 activated 
macrophages and reduce the bacterial load in a guinea pig model (Zhou 2010). In a 
2007 study by Grundner et al., a crystal structure was reported of PtpB in complex with 
the selective PtpB inhibitor (oxalylamino-methylene)-thiophene sulfonamide (OMTS – 
Figure 7A). In this structure, while PtpB was seen to adopt a simplified PTP fold with 
features of conventional PTPs, two key differences were noted. First, PtpB contains a 
disordered, acidic loop and a flexible, two-helix lid that covers the active site, and 
inhibitor binding promotes a large hinge motion of one helix in the lid to form a 
hydrophobic hairpin and a channel that leads to the catalytic cysteine. Second, the 30-
residue disordered loop folds to form a new helix bordering the active site. With such 
structural differences from other PTPs, there could be potential selectivity for targeting 
	12 
PtpB over other phosphatases (Grundner 2005). Interestingly, two OMTS molecules 
were found bound in the crystal structure, raising the possibility of two phosphotyrosine 
binding sites (Grundner 2007). In these binding conformations, we noted that the 
sulfonamides of each OMTS molecule reside ~11-12 Å apart from one another (Figure 
7B), making key polar interactions with water molecules and protein backbone amides 
and side chains (e.g. Arg59, Arg63, His94, Glu129, and Arg136). Since the two 
sulfonamides of our compound 1 analogs are also ~11-12 Å apart, we envisioned that 
this analog series might also be capable of inhibiting Mtb PtpB in a conformation that 
would bridge across the two OMTS molecules. This raises the possibility that this class 
of molecules could inhibit the two GroEL homologs to target actively replicating 
mycobacteria and dormant ones in granulomas, as well as inhibiting PtpB to target 
intracellular Mtb that are evading host cell immune responses. Thus, this class of 
inhibitors could be effective against all stages of Mtb infection. The present study was 
designed to explore the possibility of such dual-targeting GroEL/ES and PtpB inhibitors 
in vitro and in cell culture, with future studies envisioned to build from the established 
structure-activity relationships (SAR) to further optimize lead candidates for evaluating in 
animal infection models.  
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        A)  
                                         
            B)  
            
Figure 7 – Crystal structure of OMTS bound in PtpB. A. Structure of OMTS molecule. B. 
Two molecules of OMTS bound in the PtpB active site making key polar interactions. 
Image adapted from 2OZ5 crystal structure (Grundner 2007). When bound, the 
sulfonamides of each OMTS molecule reside ~11-12 Å apart, similar to our compound 1 
analog inhibitors. 
~11-12	Å	
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RESULTS AND DISCUSSION 
Identifying the efficacies of compound 1 analogs for inhibiting the GroEL/ES-
mediated folding cycle.  
 
 
Scheme 1.  Synthesis of the R- and L-series of half-molecules. (a) R1-SO2Cl, pyridine, 
CH2Cl2, rt.; (b) BBr3, CH2Cl2, rt.   
 
Extending from our previous studies that explored the bis-sulfonamide full-
molecule series (compounds 1-34 – see Tables S1-S3 in the Appendix), a library of half-
molecule analogs that had the R1-substituted sulfonamide end caps on either the Right 
(R-series) or Left (L-series) sides of the 2-phenylbenzoxazole core (Scheme 1) was 
synthesized (Abdeen 2016, Abdeen 2018). Representative synthetic protocols and 
complete compound characterizations (1H-NMR, MS, and RP-HPLC) are presented in 
the Experimental section. These syntheses resulted in the development of 58 new half-
molecules – 29 of each of the R- and L-series analogs. As we previously found that aryl-
sulfonamides were the most potent GroEL/ES inhibitors, we primarily developed analogs 
bearing substituted phenyl-sulfonamides. Furthermore, we biased the analogs to contain 
a variety of halide substituents and substitution patterns as our previous antibacterial 
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study indicated that halide-bearing compounds were typically more effective at inhibiting 
bacterial proliferation than compounds with other substituents (Abdeen 2018).   
We next employed a series of well-established biochemical assays to evaluate 
the inhibitory effects of the new half-molecules against the GroEL/ES chaperonin 
system. For these assays, we used E. coli GroEL/ES as a surrogate as obtaining 
functional GroEL oligomeric rings from Mtb has so far proven elusive. As in previous 
studies (Abdeen 2016; Johnson 2014), we employed two chaperonin-mediated folding 
assays using malate dehydrogenase (MDH) and rhodanese (Rho) as the unfolded 
reporter enzymes. Schematics of these assays are outlined in Figure 5, with detailed 
protocols presented in the Experimental section. IC50 results for the testing of 
compounds in these two assays are shown in Tables 5-16 in the Appendix section. 
While the full-molecules had been evaluated in these assays in the previous studies, we 
have also included their IC50 results in Tables 5-16 in the Appendix section for 
completeness. As visualized in the correlation plot in Figure 8A, compounds were nearly 
equipotent at inhibiting both of the GroEL/ES-mediated folding assays. As structure-
activity relationships (SAR) for full-molecule series have been more thoroughly 
discussed for these assays in the previous studies, we will primarily present SAR 
comparisons between the full- vs. half-molecule scaffolds herein. In this context, the full-
molecules were significantly more potent than the half-molecules were. We further 
counter-screened and evaluated compounds for their ability to inhibit native MDH and 
Rho to identify false-positives that simply inhibit the enzymatic reporter reactions of the 
coupled folding assays. While some compounds were found to inhibit either the native 
MDH activity or the native rhodanese activity, only one compound, 28R, inhibited in both 
native assays and the IC50 values for this compound, as well as the other compounds 
that inhibited in either native assay, were much larger than the IC50 values for the 
refolding assays (Tables 5-16 in the Appendix section and Figure 8B). These results 
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suggest that the inhibitors are on target for inhibiting the GroEL/ES-mediated folding 
cycle. 
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Figure 8 – Correlation plots comparing GroEL/ES-mediated substrate folding and native 
reporter enzyme inhibition results. A. Compounds inhibit nearly equipotently in both 
refolding assays, suggesting that compounds are on-target for inhibiting GroEL/ES. B. 
Correlation plot of IC50 values for compounds tested in the native MDH and native Rho 
reporter enzymatic counter-screens. Only compound 28R inhibited in both native assay 
counter-screens and the IC50 along with the IC50 values for compounds that inhibited in 
either native assay counter-screen were much larger than those for the refolding assays, 
suggesting that compounds are on-target for GroEL/ES and not the enzymatic reporter 
reactions. Results plotted in the grey zones represent IC50 values higher than the 
maximum concentrations listed. Blue values represent half-molecules and red values 
represent full-molecules. 
 
Compound 1 analogs are largely ineffective against M. smegmatis, but some 
modestly inhibit the proliferation of M. tuberculosis. 
 We next evaluated how effective our GroEL/ES inhibitors would be at inhibiting 
the proliferation of mycobacteria in liquid culture. In our own lab, we first screened our 
inhibitors against M. smegmatis, which is a non-pathogenic bacterium found in water 
and soil that is often used as a surrogate for initial high-throughput screening of Mtb 
inhibitors, albeit with varying levels of success (He 2010). Detailed procedures for the 
proliferation assay are presented in the Experimental section. Briefly, test compounds 
were incubated in dilution series with M. smegmatis for 24 h and an EC50 was 
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determined from OD600 readings. Unfortunately, very few compounds inhibited M. 
smegmatis growth, and the ones that did had high EC50 values (Tables 5-16 in the 
Appendix section). Intriguingly, while the half-molecules were poor GroEL/ES inhibitors, 
four were able to inhibit M. smegmatis proliferation (L36, L38-o, L39-o, and L39-p), 
which may indicate off-target effects (Figure 9). While the results from the M. smegmatis 
proliferation testing were less encouraging than we had hoped for, previous studies have 
also found that M. smegmatis is not necessarily a good screening substitute for M. 
tuberculosis (Altaf 2010). This is emphasized by the fact that even current tuberculosis 
therapeutics are not very effective against M. smegmatis (e.g. pyrazinamide and 
isoniazid). Thus, we further evaluated these compounds in an established M. 
tuberculosis proliferation assay with our collaborators at the Infectious Disease 
Research Institute in Seattle, Washington. An overview of this assay protocol is 
presented in the Experimental section. Briefly, test compounds (single concentrations of 
200 µM) were incubated with Mtb for 5 days and then plates were analyzed for 
mycobacterial growth and % inhibition values calculated (Tables 5-16 in the Appendix 
section). Compounds exhibiting >50% inhibition were then re-screened in dose-
response format to determine EC50 values. On processing the results from this assay, 
we were happy to see that there were 36 analogs that were more potent at inhibiting M. 
tuberculosis proliferation than inhibiting M. smegmatis with 15 compounds having an 
EC50 under 100 µM. Compounds 20R and 20L were two of the most potent compounds 
against Mtb, having an EC50 value of 26 µM and 59 µM respectively (Tables 5-16 in the 
Appendix section and Figure 10). For inhibiting Mtb, the full-molecules were more 
effective than the half-molecules, which is consistent with the results for the GroEL/ES-
mediated refolding assays. With this being an exploratory study, having compounds that 
act on Mtb at these potencies are promising initial results that future SAR studies can 
further optimized from. 
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Figure 9 – Correlation plot comparing GroEL/ES-mediated substrate folding with M. 
smegmatis bacterial growth inhibition results. Green values represent tuberculosis 
antibiotics. While compound 1 analogs were mostly ineffective against M. smegmatis, 
many current tuberculosis antibiotics were not very effective as well. Thus, follow-up 
screening against M. tuberculosis was warranted to see if molecules would also be more 
effective against the human pathogen. 
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Figure 10 – Correlation plot comparing M. smegmatis with M. tuberculosis bacterial 
growth inhibition results. Compounds that had less than 50% inhibition in the single 
concentration Mtb testing were assumed to have EC50 values >200 µM. There are 36 
compounds that are more potent towards M. tuberculosis with 15 compounds having 
EC50 values below 100 µM. Lead compounds 20R and 20L have an EC50 values of 26 
µM and 59 µM respectively. 
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While compounds can inhibit the human HSP60/10 chaperonin system in vitro, 
many display moderate-to-low cytotoxicity to human cells in culture. 
A caveat to targeting Mtb GroEL is that human HSP60 is moderately conserved 
(48% sequence identity with E. coli GroEL), which raises concern of potential off-target 
effects against human cells. However, the HSP60/10 chaperonin system is localized 
within the mitochondrial matrix of human cells, which is highly impermeable to 
penetration by small molecules. Thus, even if compounds can inhibit HSP60/10 
biochemical functions in-vitro, they may never reach and inhibit the chaperonin system in 
the mitochondrial matrix, permitting selective targeting of bacteria over human cells 
(Cheng 1989). Nonetheless, we counter-screened compounds in our standard 
HSP60/10-dMDH folding assay, which was analogous to the GroEL/ES-dMDH assays 
so that IC50 results could be directly compared between the two chaperonin systems. A 
detailed protocol for this assay is presented in the Experimental section, with results 
presented in Tables 5-16 of the Appendix section. While compounds were able to inhibit 
human HSP60/10, there were inhibitors that showed a greater selectivity towards E. coli 
GroEL/ES over human HSP60/10, with ~20 compounds showing around a 10-fold 
greater selectivity towards E. coli GroEL/ES (Figure 11). As with GroEL/ES, the full-
molecules were more potent at inhibiting HSP60/10 than the half-molecules were. Lead 
compounds in this study were compounds 20R, and 20L, having IC50 values under 5 µM 
for the GroEL/ES dMDH refolding mechanism. When compared to human HSP60/10 
dMDH refolding, both these compounds have >8-fold selectivity for GroEL/ES over 
human. Future SAR studies will need to be performed to optimize this series of 
compounds, but the initial selectivity towards bacterial GroEL/ES is promising in the 
development of compound 1 inhibitor analogs.  
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Figure 11 – Correlation plots comparing human HSP60/10-dMDH with GroEL/ES-dMDH 
folding inhibition. Compounds towards the top and left of the graph exhibit greater 
selectivity towards E. coli GroEL/ES over human HSP60/10. 
 
 We next evaluated all the compounds in two Alamar Blue-based cell viability 
assays, where compounds were incubated with human liver (THLE-3) or kidney (HEK 
293) cells over a 48 h time period. A detailed protocol for these assays is presented in 
the Experimental section, with cell viability results (cytotoxicity CC50 values) presented in 
Tables 5-16 in the Appendix. In general, the half-molecules exhibited higher CC50 values 
than the full-molecules, which would not be surprising since they were also weaker 
HSP60/10 inhibitors; however, as evident in Figure 12, there is no correlation between 
HSP60/10 IC50 values and cell viability CC50 values, suggesting cytotoxicities could be 
from off-target effects.  
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Figure 12 – Correlation plots comparing human HSP60/10-dMDH folding inhibition 
results with human liver and kidney cell viability results. A. HEK 293 kidney cells. B. 
THLE-3 liver cells. There is no correlation between HSP60/10 IC50 values and cell 
viability CC50 values. Compounds might not even inhibit HSP60 because it is located in 
the mitochondria and would have to cross the membrane. Cytotoxicities in cell assays 
could be from off target effects.  
 
Identifying the efficacies of compound 1 analogs for inhibiting the Mtb protein 
tyrosine phosphatase B (PtpB) virulence factor. 
 While the above studies supported the feasibility of identifying GroEL/ES 
inhibitors that could kill actively replicating Mtb (e.g. 20R and 20L), we were particularly 
intrigued by the possibility of also targeting the protein tyrosine phosphatase B (PtpB) 
virulence factor that intracellular Mtb secretes into macrophages to evade host cell 
immune responses. To investigate this possibility, we obtained a His-tagged version of 
Mtb PtpB that was previously developed by Grundner et al. to generate recombinantly 
expressed and purified enzyme (Grundner 2007). Following previously reported 
procedures by Zhou et al., which monitored for phosphatase activity using para-
nitrophenyl phosphate (pNPP), we then proceeded to evaluate all compounds in dose-
response format to obtain IC50 values (Zhou 2010). As a preliminary indication of 
selectively targeting Mtb PtpB, we counter-screened against three human phosphatases, 
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PTPN1 (PTP1B), PTPN2 (TCPTP), and PTPN5 (STEP), using analogous procedures 
(detailed protocols are presented in the Experimental section).  
When tested against M. tuberculosis PtpB, while both the full and half-molecules 
acted on the phosphatase, the full-molecules were generally more potent at inhibiting 
phosphatase activity (Tables 5-16 in Appendix) (Figure 13A). An interesting discovery for 
many of the half-molecules was that as compound concentrations increase, they first 
appear to activate the phosphatase at lower concentrations then inhibit the phosphatase 
at higher concentrations (Figure 13B). This could be a result of two half-molecules 
binding to PtpB in a manner like that previously observed for OMTS. Thus, binding of the 
first molecule at the distal site may prop the alpha-helical lid open, allowing the pNPP to 
then occupy the proximal, active site. Then, at higher concentrations, the second half-
molecule could competitively displace the pNPP from the active site, thus showing 
inhibition. It should be noted, though, that this could potentially be an artifact of this 
particular assay protocol, as we anticipate that binding to either site would compete with 
a phosphorylated peptide. Thus, IC50 values could be more potent in a physiological 
context than what we have reported, although future studies would need to confirm this.  
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Figure 13 – Representative Mtb PtpB phosphatase dose-response curves. A. compound 
2h-p and B. compound L51-p. Full-molecules inactivate the phosphatase activity while 
most half-molecules first activate the phosphatase at lower concentrations, then inhibit 
the phosphatase at higher concentrations.  
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Figure 14 – Correlation plots comparing Mtb PtpB inhibition results with human PTP’s. A. 
PTPN1 (PTP1B). B. PTPN2 (TCPTP). C. PTPN5 (STEP). 
 
While the aggregate results for the compound 1 analogs as a whole were not 
very promising for being able to selectively inhibit Mtb PtpB over the three human 
phosphatases (Figure 14), a few noteworthy compounds stood out. In particular, SAR 
reveals 10 compounds that exhibit greater than 10-fold selectivity for Mtb PtpB over the 
human phosphatases (compounds 2d-m, 2h-o, 2h-m, 2m-o, 2m-m, 2m-p, 10, 15, 20L, 
and 20R), with two divergent series that could be further explored in future optimization 
studies. The first is a series of inhibitors that selectively inhibit PtpB over human 
phosphatases, but that do not inhibit GroEL/ES-mediated refolding functions. These are 
best represented by compounds 2m-o, 2m-m, and 2m-p (Table 3). Thus, future studies 
could explore new analogs that contain a carboxylate on either the right or left-hand 
sulfonamides, while varying groups on the other side. The second contains inhibitors 
that selectively inhibit both Mtb GroEL/ES and PtpB over human HSP60/10 and 
phosphatases. This is particularly evident for analogs 20R and 20L (Table 4), which 
were also two of the most potent inhibitors of Mtb proliferation. These were unique 
compounds within this study as they were the only analogs to contain primary amines 
that would be charged under physiological conditions. Thus, future studies could explore 
new analogs that contain amines on either the right or left-hand sulfonamides, while 
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varying groups on the other side. In either case, additional areas of exploration to 
optimize inhibitors are varying the sulfonamide linkers and scaffolds other than the 2-
phenylbenzoxazole core. Once we have developed more potent and selective GroEL/ES 
and/or PtpB inhibitors, we will pursue additional studies looking at the effects of inhibiting 
Mtb PtpB in macrophage models, as well as the antibiotic efficacy of lead candidates in 
an in vivo infection model. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 In this study, we evaluated whether or not a series of previously identified 
GroEL/ES inhibitors, based on the compound 1 scaffold, would be effective at inhibiting 
the proliferation of M. tuberculosis. Furthermore, we envisioned that these molecules 
could be a dual-targeting inhibitor series capable of inhibiting the Mtb GroEL/ES 
chaperonin systems as well as the PtpB phosphatase that they secrete into 
macrophages. From this study, our results have illuminated two potential avenues for 
future optimization studies. The first is a series of compound 1 inhibitors that act solely 
on PtpB (e.g. 2m-o, 2m-m, and 2m-p) and not GroEL/ES. These compounds showed a 
greater selectivity for Mtb PtpB than human phosphatases as presented in Table 3. This 
series of compounds would target bacteria evading the host cell immune response and 
could be used in conjunction with current TB therapeutics that could target actively 
replicating bacteria. The second is a series of compound 1 inhibitors that target both Mtb 
PtpB and the GroEL/ES chaperonin systems (e.g. 20L and 20R). These compounds 
showed a greater selectivity for Mtb PtpB over human phosphatases, as well as bacterial 
GroEL/ES over human HSP60/10 (Table 4). These compounds would putatively be able 
to concomitantly target actively replicating bacteria, intracellular bacteria that are 
evading host cell immune responses, and dormant bacteria that have formed 
granulomas. Thus, we are hopeful that this could be an effective strategy to treat all 
stages of tuberculosis. Testing of inhibitors on granuloma formation has not been 
evaluated yet, and such in vivo efficacy experiments are planned for future studies once 
compounds have been further optimized.  
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Table 3 – IC50 values for phosphatase-only inhibitors. These inhibitors could be used to 
target intracellular bacteria evading the host cell immune responses. 
 
 
Assay 
2m-o (IC50) 
 
 
2m-m (IC50) 
 
 
 
2m-p (IC50) 
 
 
Kidney (HEK 293) 
cell viability 
>100 µM >100 µM >100 µM 
Liver (THLE-3) 
cell viability 
>100 µM >100 µM >100 µM 
Mtb PtpB 4.2 µM 9.9 µM 12 µM 
Human PTPN1 >100 µM >100 µM >100 µM 
Human PTPN2 >100 µM >100 µM >100 µM 
Human PTPN5 >100 µM >100 µM >100 µM 
 
Table 4 – IC50 values for dual-targeting phosphatase and GroEL/ES inhibitors. These 
compounds show a greater selectivity for Mtb PtpB over the human phosphatases and 
are also potent and selective GroEL/ES inhibitors. These compounds are envisioned to 
target actively replicating bacteria (i.e. inhibiting GroEL2), bacteria evading the host cell 
immune responses (i.e. inhibiting PtpB), and bacteria in granulomas contributing to 
latent disease (i.e. inhibiting GroEL1). 
 
 
Assay 
20R (IC50) 
 
 
20L (IC50) 
 
 
Kidney (HEK 293) cell viability 26 µM 50 µM 
Liver (THLE-3) cell viability 27 µM 36 µM 
Mtb PtpB 9.1 µM 4.4 µM 
Human PTPN1 56 µM 42 µM 
Human PTPN2 91 µM 61 µM 
Human PTPN5 75 µM 62 µM 
GroEL/ES-dMDH refolding 1.3 µM 4.6 µM 
HSP60/10-dMDH refolding 48 µM 37 µM 
Native MDH counter-screen >100 µM >100 µM 
 Native Rho counter-screen >63 µM >63 µM 
M. smegmatis EC50 71 µM 71 µM 
M. tuberculosis EC50 26 µM 59 µM 
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EXPERIMENTAL  
 
Compound synthesis and characterization.  
Unless otherwise stated, all chemicals were purchased from commercial 
suppliers and used without further purification.  Reaction progress was monitored by 
thin-layer chromatography on silica gel 60 F254 coated glass plates (EM Sciences).  
Flash chromatography was performed using a Biotage Isolera One flash 
chromatography system and eluting through Biotage KP-Sil Zip or Snap silica gel 
columns for normal-phase separations (hexanes:EtOAc gradients), or Snap KP-C18-HS 
columns for reverse-phase separations (H2O:MeOH gradients).  Reverse-phase high-
performance liquid chromatography (RP-HPLC) was performed using a Waters 1525 
binary pump, 2489 tunable UV/Vis detector (254 and 280 nm detection), and 2707 
autosampler.  For preparatory HPLC purification, samples were chromatographically 
separated using a Waters XSelect CSH C18 OBD prep column (part number 
186005422, 130 Å pore size, 5 mm particle size, 19x150 mm), eluting with a 
H2O:CH3CN gradient solvent system.  Linear gradients were run from either 100:0, 
80:20, or 60:40 A:B to 0:100 A:B (A = 95:5 H2O:CH3CN, 0.05% TFA; B = 5:95 
H2O:CH3CN, 0.05% TFA.  Products from normal-phase separations were concentrated 
directly, and reverse-phase separations were concentrated, diluted with H2O, frozen, and 
lyophilized.  For primary compound purity analyses (HPLC-1), samples were 
chromatographically separated using a Waters XSelect CSH C18 column (part number 
186005282, 130 Å pore size, 5 mm particle size, 3.0x150 mm), eluting with the above 
H2O:CH3CN gradient solvent systems.  For secondary purity analyses (HPLC-2) of final 
test compounds, samples were chromatographically separated using a Waters XBridge 
C18 column (either part number 186003027, 130 Å pore size, 3.5 mm particle size, 
3.0x100 mm, or part number 186003132, 130 Å pore size, 5.0 mm particle size, 3.0x100 
mm), eluting with a H2O:MeOH gradient solvent system.  Linear gradients were run from 
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either 100:0, 80:20, 60:40, or 20:80 A:B to 0:100 A:B (A = 95:5 H2O:MeOH, 0.05% TFA; 
B = 5:95 H2O:MeOH, 0.05% TFA).  Test compounds were found to be >95% in purity 
from both RP-HPLC analyses.  Mass spectrometry data were collected using either an 
Agilent analytical LC-MS at the IU Chemical Genomics Core Facility (CGCF), or a 
Thermo-Finnigan LTQ LC-MS in-lab.  1H-NMR spectra were recorded on either Bruker 
300 MHz or 500 MHz spectrometers.  Chemical shifts are reported in parts per million 
and calibrated to the d6-DMSO solvent peaks at 2.50 ppm.  We previously synthesized 
compounds 1-14 (including the ortho-, meta-, and para-analogs of 2a-m), as well as 15, 
16R-34R, and 16L-34L (Abdeen 2016 and Kunkle 2018).  For the new half-molecules 
synthesized and evaluated in this study, the general sulfonamide coupling step is 
presented immediately below, followed by compound characterizations for each analog 
synthesized. 
General procedure for the sulfonamide coupling step.   
To stirring mixtures of either 4-(1,3-benzoxazol-2-yl)aniline or 2-phenyl-1,3-
bezoxazol-5-amine (1 eq.) in anhydrous CH2Cl2 (5 mL) were added the respective R1-
sulfonyl chlorides (1.3 eq.), followed by anhydrous pyridine (1.3 eq.).  The reactions 
were allowed to stir at room temperature for 18 h, then chromatographed over silica 
(hexanes:EtOAc gradient), and concentrated.  If necessary, the products were further 
purified by preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized.  
Refer below for individual compound characterization data. 
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R35: N-(4-(benzo[d]oxazol-2-yl)phenyl)methanesulfonamide.  1H-NMR (300 MHz, d6-
DMSO) δ 10.35 (br s, 1H), 8.13-8.20 (m, 2H), 7.74-7.81 (m, 2H), 7.36-7.44 (m, 4H), 3.13 
(s, 3H); MS (ESI) C14H12N2O3S [M-H]- m/z expected = 287.1, observed = 286.9; HPLC-1 
= 98%; HPLC-2 = 99%. 
 
R36: N-(4-(benzo[d]oxazol-2-yl)phenyl)thiophene-2-sulfonamide.  1H-NMR (300 
MHz, d6-DMSO) δ 11.01 (br s, 1H), 8.08-8.15 (m, 2H), 7.94 (dd, J = 5.0, 1.4 Hz, 1H), 
7.72-7.80 (m, 2H), 7.68 (dd, J = 3.8, 1.4 Hz, 1H), 7.34-7.44 (m, 4H), 7.14 (dd, J = 5.0, 
3.8 Hz, 1H); MS (ESI) C17H12N2O3S2 [M-H]- m/z expected = 355.0, observed = 354.9; 
HPLC-1 = >99%; HPLC-2 = >99%. 
 
R37: N-(4-(benzo[d]oxazol-2-yl)phenyl)benzenesulfonamide.  1H-NMR (500 MHz, d6-
DMSO) δ 10.91 (br s, 1H), 8.05-8.09 (m(para), 2H), 7.84-7.88 (m, 2H), 7.72-7.78 (m, 
2H), 7.61-7.66 (m, 1H), 7.56-7.61 (m, 2H), 7.36-7.42 (m, 2H), 7.31-7.35 (m(para), 2H); 
MS (ESI) C19H14N2O3S [M-H]- m/z expected = 349.1, observed = 349.0; HPLC-1 = 
>99%; HPLC-2 = >99%. 
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R38-o: N-(4-(benzo[d]oxazol-2-yl)phenyl)-2-fluorobenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 11.22 (br s, 1H), 8.04-8.09 (m, 2H), 7.95 (td, J = 7.6, 1.7 Hz, 
1H), 7.68-7.78 (m, 3H), 7.36-7.46 (m, 4H), 7.29-7.35 (m, 2H); MS (ESI) C19H13FN2O3S 
[M-H]- m/z expected = 367.1, observed = 367.0; HPLC-1 = 99%; HPLC-2 = 97%. 
 
R38-m: N-(4-(benzo[d]oxazol-2-yl)phenyl)-3-fluorobenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.98 (br s, 1H), 8.07-8.12 (m, 2H), 7.73-7.79 (m, 2H), 7.63-7.71 
(m, 3H), 7.50-7.56 (m, 1H), 7.37-7.43 (m, 2H), 7.33-7.36 (m, 2H); MS (ESI) 
C19H13FN2O3S [M-H]- m/z expected = 367.1, observed = 366.9; HPLC-1 = >99%; HPLC-
2 = 99%. 
 
R38-p: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-fluorobenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.97 (br s, 1H), 8.11-8.16 (m, 2H), 7.94-7.99 (m, 2H), 7.78-7.84 
(m, 2H), 7.42-7.52 (m, 4H), 7.36-7.41 (m, 2H); MS (ESI) C19H13FN2O3S [M-H]- m/z 
expected = 367.1, observed = 366.9; HPLC-1 = 98%; HPLC-2 = 96%. 
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R39-o: N-(4-(benzo[d]oxazol-2-yl)phenyl)-2-chlorobenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 11.22 (br s, 1H), 8.14-8.18 (m, 1H), 8.04-8.08 (m, 2H), 7.72-7.77 
(m, 2H), 7.66 (d, J = 3.8 Hz, 2H), 7.54-7.60 (m, 1H), 7.36-7.42 (m, 2H), 7.28-7.33 (m, 
2H); MS (ESI) C19H13ClN2O3S [M-H]- m/z expected = 383.0, observed = 382.9; HPLC-1 = 
>99% HPLC-2 = 99%. 
 
R39-m: N-(4-(benzo[d]oxazol-2-yl)phenyl)-3-chlorobenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.98 (br s, 1H), 8.08-8.13 (m, 2H), 7.86 (t, J = 1.9 Hz, 1H), 7.80 
(dq, J = 7.9, 0.8 Hz, 1H), 7.72-7.78 (m, 3H), 7.63 (t, J = 7.9 Hz, 1H), 7.37-7.43 (m, 2H), 
7.33-7.37 (m, 2H); MS (ESI) C19H13ClN2O3S [M-H]- m/z expected = 383.0, observed = 
382.9; HPLC-1 = >99%; HPLC-2 = >99%. 
 
R39-p: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-chlorobenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.96 (br s, 1H), 8.07-8.11 (m, 2H), 7.83-7.87 (M, 2H), 7.73-7.79 
(m, 2H), 7.65-7.69 (m, 2H), 7.36-7.43 (m, 2H), 7.31-7.35 (m, 2H); MS (ESI) 
C19H13ClN2O3S [M-H]- m/z expected = 383.0, observed = 382.9; HPLC-1 = 99%. 
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R40: N-(4-(benzo[d]oxazol-2-yl)phenyl)-5-chlorothiophene-2-sulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 11.15 (br s, 1H), 8.10-8.17 (m, 2H), 7.73-7.81 (m, 2H), 7.57 (d, J 
= 4.1 Hz, 1H), 7.35-7.45 (m, 4H), 7.23 (d, J = 4.1 Hz, 1H); MS (ESI) C17H11ClN2O3S2 [M-
H]- m/z expected = 389.0, observed = 388.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 
R41-o: N-(4-(benzo[d]oxazol-2-yl)phenyl)-2-(trifluoromethyl)benzenesulfonamide.  
1H-NMR (500 MHz, d6-DMSO) δ 11.25 (br s, 1H), 8.18 (d, J = 7.6 Hz, 1H), 8.08-8.12 (m, 
2H), 8.02-8.05 (m, 1H), 7.84-7.93 (m, 2H), 7.73-7.79 (m, 2H), 7.36-7.43 (m, 2H), 7.31-
7.35 (m, 2H); MS (ESI) C20H13F3N2O3S [M-H]- m/z expected = 417.1, observed = 416.9; 
HPLC-1 = >99%; HPLC-2 = >99%. 
 
R41-m: N-(4-(benzo[d]oxazol-2-yl)phenyl)-3-(trifluoromethyl)benzenesulfonamide.  
1H-NMR (500 MHz, d6-DMSO) δ 11.02 (br s, 1H), 8.08-8.15 (m, 4H), 8.06 (d, J = 7.9 Hz, 
1H), 7.85 (t, J = 7.9 Hz, 1H), 7.74-7.78 (m, 2H), 7.37-7.43 (m, 2H), 7.33-7.37 (m, 2H); 
MS (ESI) C20H13F3N2O3S [M-H]- m/z expected = 417.1, observed = 416.9; HPLC-1 = 
>99%; HPLC-2 = 99%. 
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R41-p: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-(trifluoromethyl)benzenesulfonamide.  
1H-NMR (500 MHz, d6-DMSO) δ 11.11 (br s, 1H), 8.08-8.12 (m, 2H), 8.04-8.08 (m, 2H), 
7.97-8.01 (m, 2H), 7.73-7.79 (m, 2H), 7.37-7.43 (m, 2H), 7.33-7.37 (m, 2H); MS (ESI) 
C20H13F3N2O3S [M-H]- m/z expected = 417.1, observed = 416.9; HPLC-1 = >99%; HPLC-
2 = >99%. 
 
R42: N-(4-(benzo[d]oxazol-2-yl)phenyl)-3,4-dichlorobenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.55 (br s, 1H), 8.13-8.18 (m, 2H), 7.94 (d, J = 1.9 Hz, 1H), 
7.82 (d, J = 8.2 Hz, 1H), 7.71 (d, J = 8.8 Hz, 1H), 7.57-7.67 (m, 4H), 7.49 (d, J = 1.6 Hz, 
1H), 7.12 (dd, J = 8.7 Hz, 1H); MS (ESI) C19H12Cl2N2O3S [M-H]- m/z expected = 417.0, 
observed = 416.8; HPLC-1 = >99%; HPLC-2 = >99%. 
 
R43: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-fluoro-3-
(trifluoromethyl)benzenesulfonamide.  1H-NMR (500 MHz, d6-DMSO) δ 11.01 (br s, 
1H), 8.19 (dd, J = 8.4, 4.3 Hz, 1H), 8.16 (d, J = 6.3 Hz, 1H), 8.07-8.13 (m, 2H), 7.72-7.79 
(m, 3H), 7.36-7.43 (m, 2H), 7.32-7.36 (m, 2H); MS (ESI) C20H12F4N2O3S [M-H]- m/z 
expected = 435.0, observed = 434.9; HPLC-1 = >99%; HPLC-2 = >99%. 
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R44: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-chloro-3-
(trifluoromethyl)benzenesulfonamide.  1H-NMR (500 MHz, d6-DMSO) δ 11.06 (br s, 
1H), 8.16-8.19 (m, 1H), 8.06-8.13 (m, 3H), 7.97 (d, J = 8.2 Hz, 1H), 7.73-7.79 (m, 2H), 
7.36-7.43 (m, 2H), 7.32-7.36 (m, 2H); MS (ESI) C20H12ClF3N2O3S [M-H]- m/z expected = 
451.0, observed = 450.8; HPLC-1 = >99%; HPLC-2 = >99%. 
 
R45: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-chloro-3-nitrobenzenesulfonamide.  1H-
NMR (500 MHz, d6-DMSO) δ 11.17 (br s, 1H), 8.52 (d, J = 2.2 Hz, 1H), 8.09-8.13 (m, 
2H), 8.06 (dd, J = 8.5, 1.9 Hz, 1H), 8.00 (d, J = 8.5 Hz, 1H), 7.72-7.79 (m, 2H), 7.38-7.43 
(m, 2H), 7.33-7.38 (m, 2H); MS (ESI) C19H12ClN3O5S [M-H]- m/z expected = 428.0, 
observed = 427.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 
R46: N-(4-(benzo[d]oxazol-2-yl)phenyl)-5-chloro-2-methoxybenzenesulfonamide.  
1H-NMR (500 MHz, d6-DMSO) δ 10.78 (br s, 1H), 8.03-8.08 (m, 2H), 7.81 (d, J = 2.5 Hz, 
1H), 7.71-7.77 (m, 2H), 7.66 (dd, J = 9.0, 2.7 Hz, 1H), 7.34-7.42 (m, 2H), 7.29-7.33 (m, 
2H), 7.22 (d, J = 8.8 Hz, 1H), 3.87 (s, 3H); MS (ESI) C20H15ClN2O4S [M-H]- m/z expected 
= 413.0, observed = 412.9; HPLC-1 = >99%; HPLC-2 = >99%. 
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R47-o: N-(4-(benzo[d]oxazol-2-yl)phenyl)-2-methylbenzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 11.02 (br s, 1H), 8.01-8.07 (m, 2H), 7.96-8.01 (m, 1H), 7.70-7.77 
(m, 2H), 7.49-7.56 (m, 1H), 7.35-7.44 (m, 4H), 7.25-7.30 (m, 2H), 2.62 (s, 3H); MS (ESI) 
C20H16N2O3S [M-H]- m/z expected = 363.1, observed = 363.0; HPLC-1 = >99%; HPLC-2 
= >99%. 
 
R47-m: N-(4-(benzo[d]oxazol-2-yl)phenyl)-3-methylbenzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.85 (br s, 1H), 8.04-8.10 (m, 2H), 7.71-7.78 (m, 2H), 7.68 (br 
s, 1H), 7.61-7.67 (m, 1H), 7.43-7.48 (m, 2H), 7.36-7.41 (m, 2H), 7.29-7.35 (m, 2H), 2.35 
(s, 3H); MS (ESI) C20H16N2O3S [M-H]- m/z expected = 363.1, observed = 363.0; HPLC-1 
= >99%; HPLC-2 = >99%. 
 
R47-p: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-methylbenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.83 (br s, 1H), 8.04-8.09 (m, 2H), 7.72-7.78 (m, 4H), 7.36-7.43 
(m, 4H), 7.30-7.34 (m, 2H), 2.33 (s, 3H); MS (ESI) C20H16N2O3S [M-H]- m/z expected = 
363.1, observed = 363.0; HPLC-1 = >99%; HPLC-2 = >99%. 
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R48: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-ethylbenzenesulfonamide.  1H-NMR (500 
MHz, d6-DMSO) δ 10.83 (br s, 1H), 8.04-8.08 (m, 2H), 7.71-7.79 (m, 4H), 7.35-7.43 (m, 
4H), 7.30-7.35 (m, 2H), 2.63 (q, J = 7.6 Hz, 2H), 1.14 (t, J = 7.6 Hz, 3H); MS (ESI) 
C21H18N2O3S [M-H]- m/z expected = 375.1, observed = 377.0; HPLC-1 = >99%; HPLC-2 
= 99%. 
 
R49: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-vinylbenzenesulfonamide.  1H-NMR (500 
MHz, d6-DMSO) δ 10.87 (br s, 1H), 8.05-8.09 (m, 2H), 7.78-7.82 (m, 2H), 7.72-7.77 (m, 
2H), 7.64-7.68 (m, 2H), 7.35-7.41 (m, 2H), 7.30-7.34 (m, 2H), 6.76 (dd, J = 17.7, 11.0 
Hz, 1H), 5.97 (d, J = 17.7 Hz, 1H), 5.42 (d, J = 11.0 Hz, 1H); MS (ESI) C21H16N2O3S [M-
H]- m/z expected = 377.1, observed = 375.0; HPLC-1 = 98%; HPLC-2 = 98%. 
 
R50-o: N-(4-(benzo[d]oxazol-2-yl)phenyl)-2-methoxybenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.64 (br s, 1H), 8.01-8.05 (m, 2H), 7.88 (dd, J = 7.9, 1.6 Hz, 
1H), 7.71-7.77 (m, 2H), 7.56-7.62 (m, 1H), 7.35-7.41 (m, 2H), 7.28-7.32 (m, 2H), 7.18 (d, 
J = 7.9 Hz, 1H), 7.06-7.11 (m, 1H), 3.87 (s, 3H); MS (ESI) C20H16N2O4S [M-H]- m/z 
expected = 379.1, observed = 378.9; HPLC-1 = >99%; HPLC-2 = >99%. 
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R50-m: N-(4-(benzo[d]oxazol-2-yl)phenyl)-3-methoxybenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.86 (br s, 1H), 8.06-8.11 (m, 2H), 7.73-7.78 (m, 2H), 7.50 (t, J 
= 8.2 Hz, 1H), 7.38-7.43 (m, 3H), 7.33-7.37 (m, 3H), 7.20 (ddd, J = 8.2, 2.5, 0.9 Hz, 1H), 
3.79 (s, 3H); MS (ESI) C20H16N2O4S [M-H]- m/z expected = 379.1, observed = 378.9; 
HPLC-1 = >99%; HPLC-2 = >99%. 
 
R50-p: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-methoxybenzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.00 (br s, 1H), 7.89-7.93 (m, 2H), 7.40-7.46 (m, 3H), 7.33-7.40 
(m, 3H), 7.21 (d, J = 1.6 Hz, 1H), 6.88 (dd, J = 8.8, 2.2 Hz, 1H), 6.78-6.82 (m, 2H), 3.53 
(s, 3H); MS (ESI) C20H16N2O4S [M-H]- m/z expected = 379.1, observed = 379.0; HPLC-1 
= 95%; HPLC-2 = 95%. 
General procedure for the methoxy-to-hydroxy de-protection step.   
To stirring mixtures of the respective compound 50 methoxy-bearing analogs (1 
eq.) in anhydrous CH2Cl2 (5 mL) was added BBr3 (3 eq. of 1 M BBr3 solution in 
anhydrous CH2Cl2).  The reactions were allowed to stir at room temperature for 18 h 
(under argon), quenched with MeOH, then chromatographed over silica (hexanes:EtOAc 
gradient), and concentrated.  If necessary, the products were further purified by 
preparatory RP-HPLC (H2O:CH3CN gradient), concentrated, and lyophilized.  Refer 
below for individual compound characterization data. 
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R51-o: N-(4-(benzo[d]oxazol-2-yl)phenyl)-2-hydroxybenzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.81 (br s, 2H), 7.98-8.05 (m, 2H), 7.80 (dd, J = 8.1, 1.7 Hz, 
1H), 7.69-7.76 (m, 2H), 7.34-7.46 (m, 3H), 7.26-7.33 (m, 2H), 6.89-6.97 (m, 2H); MS 
(ESI) C19H14N2O4S [M-H]- m/z expected = 365.1, observed = 364.9; HPLC-1 = 97%; 
HPLC-2 = >99%. 
 
R51-m: N-(4-(benzo[d]oxazol-2-yl)phenyl)-3-hydroxybenzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.77 (br s, 1H), 10.12 (s, 1H), 7.97-8.05 (m, 2H), 7.64-7.73 (m, 
2H), 7.17-7.37 (m, 6H), 7.11-7.15 (m, 1H), 6.89-6.95 (m, 1H); MS (ESI) C19H14N2O4S [M-
H]- m/z expected = 365.1, observed = 365.0; HPLC-1 = >99%; HPLC-2 = >99%. 
 
R51-p: N-(4-(benzo[d]oxazol-2-yl)phenyl)-4-hydroxybenzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.43 (s, 1H), 10.15 (s, 1H), 8.12-8.19 (m, 2H), 7.54-7.69 (m, 
6H), 7.44 (d, J = 2.0 Hz, 1H), 7.11 (dd, J = 8.8, 2.0 Hz, 1H), 6.79-6.87 (m, 2H); MS (ESI) 
C19H14N2O4S [M-H]- m/z expected = 365.1, observed = 365.0;  
 
L35: N-(2-phenylbenzo[d]oxazol-5-yl)methanesulfonamide.  1H-NMR (300 MHz, d6-
DMSO) δ 9.82 (br s, 1H), 8.16-8.23 (m, 2H), 7.78 (d, J = 8.8 Hz, 1H), 7.58-7.67 (m, 4H), 
7.28 (dd, J = 8.7, 2.2 Hz, 1H), 2.99 (s, 3H); MS (ESI) C14H12N2O3S [M-H]- m/z expected 
= 287.1, observed = 287.0; HPLC-1 = >99%; HPLC-2 = >99%. 
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L36: N-(2-phenylbenzo[d]oxazol-5-yl)thiophene-2-sulfonamide.  1H-NMR (300 MHz, 
d6-DMSO) δ 10.51 (br s, 1H), 8.17 (dd, J = 7.7, 1.8 Hz, 2H), 7.88 (dd, J = 5.0, 1.3 Hz, 
1H), 7.72 (d, J = 8.8 Hz, 1H), 7.56-7.66 (m, 3H), 7.47-7.55 (m, 2H), 7.16 (dd, J = 8.8, 2.1 
Hz, 1H), 7.10 (dd, J = 4.9, 3.8 Hz, 1H); MS (ESI) C17H12N2O3S2 [M-H]- m/z expected = 
355.0, observed = 354.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 
L37: N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR (300 MHz, d6-
DMSO) δ 10.39 (br s, 1H), 8.11-8.18 (m, 2H), 7.75 (d, J = 7.0 Hz, 2H), 7.49-7.70 (m 7H), 
7.45 (d, J = 1.8 Hz, 1H), 7.12 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) C19H14N2O3S [M-H]- m/z 
expected = 349.1, observed = 349.0; HPLC-1 = >99%; HPLC-2 = >99%. 
 
L38-o: 2-fluoro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR (500 
MHz, d6-DMSO) δ 10.71 (br s, 1H), 8.13-8.17 (m, 2H), 7.83 (td, J = 7.6, 1.7 Hz, 1H), 
7.57-7.70 (m, 5H), 7.47-7.49 (m, 1H), 7.39-7.44 (m, 1H), 7.34 (td, J = 7.6, 1.1 Hz, 1H), 
7.15-7.18 (m, 1H); MS (ESI) C19H13FN2O3S [M-H]- m/z expected = 367.1, observed = 
367.0; HPLC-1 = >99%; HPLC-2 = >99%. 
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L38-m: 3-fluoro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.53 (br s, 1H), 8.13-8.18 (m, 2H), 7.68 (d, J = 8.8 Hz, 1H), 
7.56-7.66 (m, 5H), 7.55 (dt, J = 8.0, 1.7 Hz, 1H), 7.47-7.51 (m, 1H), 7.47 (d, J = 1.9 Hz, 
1H), 7.12 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) C19H13FN2O3S [M-H]- m/z expected = 
367.1, observed = 367.0; HPLC-1 = >99%; HPLC-2 = >99%. 
 
L38-p: 4-fluoro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR (500 
MHz, d6-DMSO) δ 10.41 (br s, 1H), 8.13-8.18 (m, 2H), 7.77-7.82 (m, 2H), 7.68 (d, J = 
8.8 Hz, 1H), 7.58-7.66 (m, 3H), 7.46 (d, J = 1.9 Hz, 1H), 7.35-7.42 (m, 2H), 7.11 (dd, J = 
8.7, 2.0 Hz, 1H); MS (ESI) C19H13FN2O3S [M-H]- m/z expected = 367.1, observed = 
366.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 
L39-o: 2-chloro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.74 (br s, 1H), 8.11-8.16 (m, 2H), 8.05 (dd, J = 8.0, 1.4 Hz, 
1H), 7.67 (d, J = 8.8 Hz, 1H), 7.57-7.65 (m, 5H), 7.50 (td, J = 7.6, 1.6 Hz, 1H), 7.46 (d, J 
= 1.9 Hz, 1H), 7.17 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) C19H13ClN2O3S [M-H]- m/z 
expected = 383.0, observed = 382.9; HPLC-1 = >99%; HPLC-2 = >99%. 
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L39-m: 3-chloro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.50 (br s, 1H), 8.13-8.18 (m, 2H), 7.77 (t, J = 1.7 Hz, 1H), 
7.66-7.72 (m, 3H), 7.54-7.65 (m, 4H), 7.47 (d, J = 2.2 Hz, 1H), 7.12 (dd, J = 8.7, 2.0 Hz, 
1H); MS (ESI) C19H13ClN2O3S [M-H]- m/z expected = 383.0, observed = 382.9; HPLC-1 = 
>99%; HPLC-2 = >99%. 
 
L39-p: 4-chloro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.46 (br s, 1H), 8.13-8.18 (m, 2H), 7.71-7.76 (m, 2H), 7.66-7.70 
(m, 1H), 7.57-7.66 (m, 5H), 7.47 (s, 1H), 7.09-7.14 (m, 1H); MS (ESI) C19H13ClN2O3S [M-
H]- m/z expected = 383.0, observed = 382.9; HPLC-1 = >99%; HPLC-2 = >99%. 
 
L40: 5-chloro-N-(2-phenylbenzo[d]oxazol-5-yl)thiophene-2-sulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.67 (br s, 1H), 8.14-8.21 (m, 2H), 7.75 (d, J = 8.8 Hz, 1H), 
7.57-7.68 (m, 3H), 7.53 (d, J = 2.0 Hz, 1H), 7.41 (d, J = 4.0 Hz, 1H), 7.15-7.21 (m, 2H); 
MS (ESI) C17H11ClN2O3S2 [M-H]- m/z expected = 389.0, observed =  
1 = >99%; HPLC-2 = >99%. 
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L41-o: N-(2-phenylbenzo[d]oxazol-5-yl)-2-(trifluoromethyl)benzenesulfonamide.  
1H-NMR (500 MHz, d6-DMSO) δ 10.78 (br s, 1H), 8.13-8.17 (m, 2H), 8.12 (d, J = 7.9 Hz, 
1H), 7.97-8.02 (m, 1H), 7.79-7.89 (m, 2H), 7.70 (d, J = 8.8 Hz, 1H), 7.57-7.66 (m, 3H), 
7.47 (d, J = 2.2 Hz, 1H), 7.17 (dd, J = 8.8, 2.2 Hz, 1H); MS (ESI) C20H13F3N2O3S [M-H]- 
m/z expected = 417.1, observed = 416.9; HPLC-1 = >99%; HPLC-2 = >99%. 
 
L41-m: N-(2-phenylbenzo[d]oxazol-5-yl)-3-(trifluoromethyl)benzenesulfonamide.  
1H-NMR (500 MHz, d6-DMSO) δ 10.55 (br s, 1H), 8.13-8.18 (m, 2H), 7.97-8.04 (m, 3H), 
7.76-7.81 (m, 1H), 7.69 (d, J = 8.8 Hz, 1H), 7.57-7.67 (m, 3H), 7.46 (d, J = 1.9 Hz, 1H), 
7.11 (d, J = 8.8, 2.2 Hz, 1H); MS (ESI) C20H13F3N2O3S [M-H]- m/z expected = 417.1, 
observed = 416.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 
L41-p: N-(2-phenylbenzo[d]oxazol-5-yl)-4-(trifluoromethyl)benzenesulfonamide.  
1H-NMR (500 MHz, d6-DMSO) δ 10.64 (br s, 1H), 8.13-8.17 (m, 2H), 7.95 (app s, 4H), 
7.69 (d, J = 8.5 Hz, 1H), 7.58-7.66 (m, 3H), 7.49 (d, J = 1.9 Hz, 1H), 7.12 (d, J = 8.8, 2.2 
Hz, 1H); MS (ESI) C20H13F3N2O3S [M-H]- m/z expected = 417.1, observed = 416.9; 
HPLC-1 = >99%; HPLC-2 = >99%. 
 
 
	43 
 
L42: 3,4-dichloro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 11.02 (br s, 1H), 8.08-8.13 (m, 2H), 8.03 (d, J = 1.9 Hz, 1H), 
7.87 (d, J = 8.5 Hz, 1H), 7.73-7.79 (m, 3H), 7.36-7.43 (m, 2H), 7.32-7.36 (m, 2H); MS 
(ESI) C19H12Cl2N2O3S [M-H]- m/z expected = 417.0, observed = 416.8; HPLC-1 = >99%; 
HPLC-2 = >99%. 
 
L43: 4-fluoro-N-(2-phenylbenzo[d]oxazol-5-yl)-3-
(trifluoromethyl)benzenesulfonamide.  1H-NMR (500 MHz, d6-DMSO) δ 10.53 (br s, 
1H), 8.15 (d, J = 7.3 Hz, 2H), 8.02-8.09 (m, 2H), 7.66-7.7.3 (m, 2H), 7.57-7.66 (m, 3H), 
7.48 (s, 1H), 7.11 (dd, J = 8.7, 1.7 Hz, 1H); MS (ESI) C20H12F4N2O3S [M-H]- m/z 
expected = 435.0, observed = 434.9; HPLC-1 = >99%; HPLC-2 = >99%. 
 
L44: 4-chloro-N-(2-phenylbenzo[d]oxazol-5-yl)-3-
(trifluoromethyl)benzenesulfonamide.  1H-NMR (500 MHz, d6-DMSO) δ 10.60 (br s, 
1H), 8.16 (d, J = 6.9 Hz, 2H), 8.10 (s, 1H), 7.88-7.97 (m, 2H), 7.71 (d, J = 8.8 Hz, 1H), 
7.58-7.67 (m, 3H), 7.46-7.49 (m, 1H), 7.10 (dd, J = 8.8, 1.9 Hz, 1H); MS (ESI) 
C20H12ClF3N2O3S [M-H]- m/z expected = 451.0, observed = 450.9; HPLC-1 = >99%; 
HPLC-2 = >99%. 
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L45: 4-chloro-3-nitro-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-
NMR (500 MHz, d6-DMSO) δ 10.69 (br s, 1H), 8.42 (d, J = 1.3 Hz, 1H), 8.16 (d, J = 6.6 
Hz, 2H), 7.91-7.97 (m, 2H), 7.72 (d, J = 8.5 Hz, 1H), 7.58-7.67 (m, 3H), 7.52 (d, J = 1.6 
Hz, 1H), 7.13 (dd, J = 8.7, 2.0 Hz, 1H); MS (ESI) C19H12ClN3O5S  [M-H]- m/z expected = 
428.0, observed = 427.9; HPLC-1 = 99%; HPLC-2 = 99%. 
 
L46: 5-chloro-2-methoxy-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-
NMR (300 MHz, d6-DMSO) δ 10.29 (br s, 1H), 8.11-8.17 (m, 2H), 7.65-7.69 (m, 2H), 
7.55-7.64 (m, 4H), 7.45 (d, J = 2.0 Hz, 1H), 7.23 (d, J = 8.9 Hz, 1H), 7.16 (dd, J = 8.8, 
2.1 Hz, 1H), 3.92 (s, 3H); MS (ESI) C20H15ClN2O4S [M-H]- m/z  
 
L47-o: 2-methyl-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.52 (br s, 1H), 8.14 (dd, J = 7.5, 1.8 Hz, 2H), 7.89 (d, J = 7.5 
Hz, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.55-7.64 (m, 3H), 7.44-7.52 (m, 1H), 7.42 (d, J = 2.1 
Hz, 1H), 7.30-7.39 (m, 2H), 7.12 (dd, J = 8.8, 2.1 Hz, 1H), 2.61 (s, 3H); MS (ESI) 
C20H16N2O3S [M-H]- m/z expected = 363.1, observed = 363.0; HPLC-1 = >99%; HPLC-2 
= >99%. 
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L47-m: 3-methyl-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.36 (br s, 1H), 8.12-8.18 (m, 2H), 7.67 (d, J = 8.7 Hz, 1H), 
7.51-7.64 (m, 5H), 7.46 (d, J = 2.0 Hz, 1H), 7.38-7.43 (m, 2H), 7.12 (dd, J = 8.8, 2.1 Hz, 
1H), 2.32 (s, 3H); MS (ESI) C20H16N2O3S [M-H]- m/z expected = 363.1, observed = 
363.0; HPLC-1 = >99%; HPLC-2 = >99%. 
 
L47-p: 4-methyl-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.32 (br s, 1H), 8.12-8.17 (m, 2H), 7.57-7.68 (m, 6H), 7.45 (d, J 
= 1.9 Hz, 1H), 7.30-7.36 (m, 2H), 7.12 (dd, J = 8.7, 2.0 Hz, 1H), 2.31 (s, 3H); MS (ESI) 
C20H16N2O3S [M-H]- m/z expected = 363.1, observed = 362.9; HPLC- 
 
 
L48: 4-ethyl-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR (500 
MHz, d6-DMSO) δ 10.35 (br s, 1H), 8.15 (dd, J = 7.9, 1.6 Hz, 2H), 7.64-7.70 (m, 3H), 
7.57-7.64 (m, 3H), 7.46 (d, J = 2.2 Hz, 1H), 7.37 (d, J = 8.2 Hz, 2H), 7.13 (dd, J = 8.7, 
2.0 Hz, 1H), 2.62 (q, J = 7.6 Hz, 2H), 1.13 (t, J = 7.6 Hz, 3H); MS (ESI) C21H18N2O3S [M-
H]- m/z expected = 377.1, observed = 377.0; HPLC-1 = 99%; HPLC-2 = 99%. 
388.9; HPLC-1 = 98%; HPLC-2 = 99%. 
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L49: N-(2-phenylbenzo[d]oxazol-5-yl)-4-vinylbenzenesulfonamide.  1H-NMR (500 
MHz, d6-DMSO) δ 10.38 (br s, 1H), 8.15 (dd, J = 8.0, 1.4 Hz, 2H), 7.71 (d, J = 8.5 Hz, 
2H), 7.67 (d, J = 8.8 Hz, 1H), 7.57-7.65 (m, 5H), 7.46 (d, J = 1.9 Hz, 1H), 7.12 (dd, J = 
8.8, 2.2 Hz, 1H), 6.75 (dd, J = 17.7, 11.0 Hz, 1H), 5.95 (d, J = 17.7 Hz, 1H), 5.41 (d, J = 
11.0 Hz, 1H); MS (ESI) C21H16N2O3S [M-H]- m/z expected = 375.1, observed = 374.9; 
HPLC-1 = 97%; HPLC-2 = 96%. 
 
L50-o: 2-methoxy-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.10 (br s, 1H), 8.11-8.15 (m, 2H), 7.76 (d, J = 7.9, 1.6 Hz, 1H), 
7.56-7.65 (m, 4H), 7.51-7.56 (m, 1H), 7.45 (d, J = 1.9 Hz, 1H), 7.16 (dd, J = 8.8, 1.9 Hz, 
2H), 6.98-7.03 (m, 1H), 3.92 (s, 3H); MS (ESI) C20H16N2O4S [M-H]- m/z expected = 
379.1, observed = 378.9; HPLC-1 = >99%; HPLC-2 = 99%. 
 
L50-m: 3-methoxy-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(500 MHz, d6-DMSO) δ 10.37 (br s, 1H), 8.13-8.17 (m, 2H), 7.68 (d, J = 8.8 Hz, 1H), 
7.57-7.66 (m, 3H), 7.4.7 (d, J = 1.9 Hz, 1H), 7.44 (t, J = 8.0 Hz, 1H), 7.29-7.32 (m, 1H), 
7.25-7.28 (m, 1H), 7.12-7.18 (m, 2H), 3.75 (s, 3H); MS (ESI) C20H16N2O4S [M-H]- m/z 
expected = 379.1, observed = 379.0; HPLC-1 = >99%; HPLC-2 = >99%. 
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L50-p: 4-methoxy-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.25 (br s, 1H), 8.15 (dd, J = 7.7, 1.8 Hz, 2H), 7.64-7.71 (m, 
3H), 7.56-7.63 (m, 3H), 7.45 (d, J = 2.0 Hz, 1H), 7.12 (dd, J = 8.8, 2.1 Hz, 1H), 7.04 (d, J 
= 8.9 Hz, 2H), 3.76 (s, 3H); MS (ESI) C20H16N2O4S [M-H]- m/z expected = 379.1, 
observed = 378.9; HPLC-1 = >99%; HPLC-2 = >99%. 
 
L51-o: 2-hydroxy-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.52 (br s, 2H), 8.10-8.18 (m, 2H), 7.55-7.72 (m, 5H), 7.48 (d, J 
= 2.0 Hz, 1H), 7.33-7.42 (m, 1H), 7.20 (dd, J = 8.8, 2.1 Hz, 1H), 6.93 (d, J = 8.1 Hz, 1H), 
6.86 (t, J = 7.6 Hz, 1H); MS (ESI) C19H14N2O4S [M-H]- m/z expected = 365.1, observed = 
365.0; HPLC-1 = 96%; HPLC-2 = 98%. 
 
L51-m: 3-hydroxy-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.33 (br s, 1H), 10.10 (br s, 1H), 8.16 (dd, J = 7.7, 1.9 Hz, 2H), 
7.68 (d, J = 8.8 Hz, 1H), 7.56-7.66 (m, 3H), 7.46 (d, J = 2.0 Hz, 1H), 7.32 (t, J = 8.0 Hz, 
1H), 7.18 (d, J = 8.1 Hz, 1H), 7.09-7.15 (m, 2H), 6.94 (dd, J = 7.8, 2.0 Hz, 1H); MS (ESI) 
C19H14N2O4S [M-H]- m/z expected = 365.1, observed = 365.0; HPLC-1 = >99%; HPLC-2 
= 98%. 
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L51-p: 4-hydroxy-N-(2-phenylbenzo[d]oxazol-5-yl)benzenesulfonamide.  1H-NMR 
(300 MHz, d6-DMSO) δ 10.67 (br s, 1H), 10.52 (br s, 1H), 8.06 (d, J = 8.8 Hz, 2H), 7.71-
7.79 (m, 2H), 7.64-7.71 (m, 2H), 7.34-7.44 (m, 2H), 7.30 (d, J = 8.8 Hz, 2H), 6.84-6.91 
(m, 2H); MS (ESI) C19H14N2O4S [M-H]- m/z expected = 365.1, observed = 365.0; HPLC-1 
= 98%; HPLC-2 = 97%. 
General materials and methods for biochemical & cell-based experiments.   
DH5α and BL21 (DE3) E. coli cells were purchased from New England Biolabs, 
and Rosetta™ 2 (DE3) E. coli cells from EMD Millipore. The Mycobacterium smegmatis 
proliferation assay used the (Trevisan) Lehmann and Neumann strain, which was 
obtained from the ATCC (#700084). The Mycobacterium tuberculosis proliferation assay 
used an H37Rv strain that researchers at the Infectious Disease Research Institute 
(Seattle, WA, USA) previously engineered to express a codon-optimized mCherry 
fluorescent protein (TOPred).[REF] The human cell viability assays used HEK 293 
kidney cells (CRL-1573) and THLE-3 liver cells (CRL-11233) obtained from the ATCC.  
Antibiotics were used in following concentrations when appropriate; Kanamycin (34 
µg/mL), Ampicillin (50 µg/mL), Chloramphenicol (30 µg/mL) and Streptomycin (100 
µg/mL).   
NOTE: While the following experimental protocols have been reported in previous 
studies, by us and others, we have reported detailed descriptions of each here to 
maintain rigor, reproducibility, and transparency throughout our studies. 
E. coli GroEL and GroES protein expression and purification 
E. coli GroEL was expressed from a trc-promoted and Amp(+) resistance marker 
plasmid in DH5α. E. coli cells. GroES was expressed from a T7-promoted and Amp(+) 
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resistance plasmid in E. coli BL21 (DE3) cells. Transformed colonies were plated onto 
Ampicillin-treated LB agar and incubated for 24 h at 37°C.  Cells were then grown at 
37°C in Ampicillin-treated LB medium until an OD600 of 0.5 was reached, then were 
induced with 0.8 mM IPTG and continued to grow for 2-3 h at 37°C. The cultures were 
centrifuged at 8,000 rpm and the cell pellets were collected and re-suspended in Buffer 
A (50 mM Tris-HCl, pH 7.4, and 20 mM NaCl) supplemented with EDTA-free complete 
protease inhibitor cocktail (Roche). The combined suspension was lysed by sonication, 
the lysate was centrifuged at 14,000 rpm, and the clarified lysate was passed through a 
0.45 µM filter (Millipore). 
Anion exchange purification:  
 The filtered lysate was loaded onto a GE HiScale Anion exchange column (Q 
Sepharose fast flow anion exchange resin) that was equilibrated with 2 column volumes 
of Buffer A.  The loaded column was washed with 4 column volumes of Buffer A 
containing 30% of Buffer B (50 mM Tris-HCl, pH 7.4, and 1 M NaCl), then bound protein 
was eluted with a 30-60% gradient elution of Buffer B. Protein-containing fractions, as 
identified by SDS-PAGE, were collected, spin concentrated using a 10 kDa Amicon 
Ultra-15 centrifugal filter (EMD Millipore), and dialyzed overnight with 10 kDa 
SnakeSkin™ dialysis tubing (Thermo Scientific) at 4°C in 2 L of 50 mM Tris-HCl, pH 7.4, 
and 150 mM NaCl solution.  
Size exclusion chromatography:  
 The dialyzed protein was loaded onto a Superdex 200 column (HiLoad 26/600, 
GE) column that was equilibrated with 2 column volumes of 50 mM Tris-HCl, pH 7.4 and 
150 mM NaCl solution. The loaded column was eluted with 1 column volume of 100% 50 
mM Tris-HCl, pH 7.4 and 150 mM NaCl solution and the column was washed with 2 
column volumes of the same solution. Protein-containing fractions, as identified by SDS-
PAGE, were collected, spin concentrated using a 10 kDa Amicon Ultra-15 centrifugal 
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filter (EMD Millipore), and dialyzed overnight with 10 kDa SnakeSkin™ dialysis tubing 
(Thermo Scientific) at 4°C in 2 L of 50 mM Tris-HCl, pH 7.4, and 150 mM NaCl solution.  
The final protein concentration was determined by Coomassie Protein Assay Kit 
(Thermo Scientific). Batches of protein for testing were stored at 4°C for up to one month 
then discarded. 
Human HSP60 and HSP10 protein expression and purification 
Human HSP60 purification: 
 For generating human mitochondrial HSP60 (mtHSP60), a previously reported 
pET21-HSP60 plasmid with an N-terminal octa-Histidine tag was transformed into 
Rosetta™ 2 (DE3) pLysS E. coli cells for over-expression (Abdeen 2016). Cells were 
grown at 37°C in LB / ampicillin / chloramphenicol medium until an OD600 of 0.5 was 
reached, then cultures were induced with 0.5 mM IPTG and continued to grow for 2-3 h 
at 25°C.  Cells were centrifuged at 14,000 rpm, and the cell pellet was suspended in 50 
mL of lysis buffer composed of 100 mM Tris-HCl, pH 7.7, 10 mM MgSO4, 1 mM β-ME, 
5% glycerol, 0.1% triton X-100, 1500 Units DNAase, 50 mg/ml lysozyme, and one tablet 
of EDTA-free complete protease inhibitor cocktail (Roche).  Cells were homogenized 
and passed through a microfluidizer, washing with buffer containing 10 mM Tris-HCl, pH 
7.7, 5% glycerol, and 0.1% triton X-100.  
1st nickel column purification and His-tag cleavage:  
 The cell lysate was centrifuged at 14,000 rpm, then the clarified lysate was 
supplemented with 10 mM imidazole, passed through a 0.2 µM filter (Millipore), and 
loaded onto a nickel-agarose resin column that was equilibrated with 2 column volumes 
of 20 mM Tris-HCl pH, 7.7, 5% glycerol, 200 mM NaCl, and 10 mM imidazole.  The 
loaded column was washed with 6 column volumes of 50 mM imidazole, then bound 
HSP60 was eluted with 500 mM imidazole.  Fractions that were enriched with the His-
tagged mtHSP60 were collected, concentrated, dialyzed at room temperature for 2 h in 4 
	51 
L of 20 mM Tris-HCl, pH 7.7, 200 mM NaCl, and 5% glycerol.  Proteolytic cleavage of 
the His-tag was next performed by addition of His-tagged TEV protease at a 1:10 (w:w) 
ratio, while dialyzing over night at 4°C against 4 L of 20 mM Tris-HCl, pH 7.7, 200 mM 
NaCl, and 5% glycerol buffer. 
2nd nickel column purification:   
 The protein sample was loaded onto a second nickel-agarose resin column that 
was equilibrated with 20 mM Tris-HCl, pH 7.7, 5% glycerol, 10 mM NaCl, and 10 mM 
imidazole.  With this column, undigested His-tagged mtHSP60 can be separated from 
digested His-tag removed mtHSP60.  The unbound fractions enriched with His-tag 
cleaved mtHSP60 were collected, and anion exchange chromatography was performed 
on the same day. 
Anion exchange purification of His-tag removed mtHSP60:  
 The protein sample was next loaded onto an anion-exchange column that was 
equilibrated with 20 mM Tris-HCl, pH 7.7, and 5% glycerol.  Bound proteins were eluted 
from the column with a linear gradient of 100-400 mM NaCl.  Fractions enriched with 
mtHSP60 were collected, concentrated, and dialyzed in storage buffer (20 mM Tris-HCl, 
pH 7.7, 300 mM NaCl, 5% glycerol, and 10 mM MgCl2) using 10 kDa SnakeSkin™ 
dialysis tubing (Thermo Scientific).  The concentration of protein was determined by 
Coomassie Protein Assay Kit (Thermo Scientific).  Batches of HSP60 protein for testing 
were stored at 4°C for up to two weeks, then discarded.  
Human HSP10 purification: 
 Human HSP10 (mtHSP10) was expressed from a T7-promoted (pET3a-HSP10) 
plasmid in Rosetta™ 2 (DE3) cells.  Cells were grown at 37°C in LB / kanamycin / 
chloramphenicol medium until an OD600 of 0.5 was reached, then were induced with 0.5 
mM IPTG and continued to grow for 2-3 h at 37°C. Cells were centrifuged at 8,000 rpm, 
and the cell pellet was suspended in 50 mL of lysis buffer composed of 50 mM NaOAc, 
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pH 7.4, 20 mM NaCl, and one tablet of EDTA-free complete protease inhibitor cocktail 
(Roche). Once re-suspended, the sample was lysed by sonication. 
Cation exchange purification:  
 The cell lysate was centrifuged at 14,000 rpm and the cell pellet was re-
suspended in Buffer A (50 mM NaOAc, pH 4.5, and 20 mM NaCl), supplemented with 
EDTA-free complete protease inhibitor cocktail (Roche) and lysed by sonication. 
Clarified cell lysate was loaded on a cation exchange column (SP Sepharose fast flow 
resin, GE) and eluted with a linear NaCl gradient using Buffer B (50 mM NaOAc, pH 4.5, 
and 1 M NaCl). Fractions containing HSP10 were collected, spin concentrated using a 
10 kDa filter canonicals, and dialyzed overnight with 10 kDa SnakeSkin™ dialysis tubing 
(Thermo Scientific) in a storage buffer composed of 50 mM Tris-HCl, pH 7.4 and 150 
mM NaCl. 
Size exclusion chromatography:  
 The dialyzed protein was loaded onto a GE HiScale Size Exclusion column that 
was equilibrated with 2 column volumes of 50 mM Tris-HCl, pH 7.4 and 150 mM NaCl 
solution. The loaded column was eluted with 1 column volume of 100% 50 mM Tris-HCl, 
pH 7.4 and 150 mM NaCl solution and the column was washed with 2 column volumes 
of the same elution buffer. Fractions were analyzed under a gel stain and fractions that 
contained protein were collected, were collected, spin concentrated using a 10 kDa filter 
canonicals, and dialyzed overnight with 10 kDa SnakeSkin™ dialysis tubing (Thermo 
Scientific) at 4°C in 2L of 50 mM Tris-HCl, pH 7.4, 300 mM NaCl, and 1 mM DTT 
solution. The concentration of protein was determined by Coomassie Protein Assay Kit 
(Thermo Scientific). Batches of HSP10 protein for testing were stored at 4°C for up to 
three weeks, then discarded. 
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Evaluating compounds for inhibition in the GroEL/ES and HSP60/10 mediated 
dMDH refolding assays.  
Reagent preparation: 
 For these assays, four primary reagent stocks were prepared: 1) GroEL/ES-
dMDH or HSP60/10-dMDH binary complex stock; 2) ATP initiation stock; 3) EDTA 
quench stock; 4) MDH enzymatic assay stock.  Denatured MDH (dMDH) was prepared 
by 2-fold dilution of MDH (5 mg/ml, soluble pig heart MDH from Roche, product 
#10127248001) with denaturant buffer (7 M guanidine-HCl, 200 mM Tris, pH 7.4, and 50 
mM DTT). MDH was completely denatured by incubating at room temperature for 45 
min. The binary complex solutions were prepared by slowly adding the dMDH stock to a 
stirring stock with GroEL (or HSP60) in folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM 
KCl, 10 mM MgCl2, and 1 mM DTT), followed by addition of GroES (or HSP10).  The 
binary complex stocks were prepared immediately prior to dispensing in to the assay 
plates and had final protein concentrations of 83.3 nM GroEL (Mr 800 kDa) or HSP60 
(Mr 400 kDa), 100 nM GroES or HSP10 (Mr 70 kDa), and 20 nM dMDH in folding buffer.  
For the ATP initiation stock, ATP solid was diluted into folding buffer to a final 
concentration of 2.5 mM.  Quench solution contained 600 mM EDTA (pH 8.0).  The MDH 
enzymatic assay stock consisted of 20 mM sodium mesoxalate and 2.4 mM NADH in 
reaction buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, and 1 mM DTT). 
Assay protocol:  
 First, 30 µL aliquots of the GroEL/ES-dMDH or HSP60/10-dMDH binary complex 
stocks were dispensed into clear, 384-well polystyrene plates.  Next, 0.5 µL of the 
compound stocks (10 mM to 4.6 µM, 3-fold dilutions series in DMSO) were added by 
pin-transfer (V&P Scientific).  The chaperonin-mediated refolding cycles were initiated by 
addition of 20 µL of ATP stock (reagent concentrations during refolding cycle: 50 nM 
GroEL or HSP60, 60 nM GroES or HSP10, 12 nM dMDH, 1 mM ATP, and compounds of 
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100 µM to 46 nM, 3-fold dilution series), and the refolding reactions incubated at 37°C. 
The incubation times were determined from refolding time-course control experiments 
until they reached ~90% completion of refolding of the denatured MDH – generally ~20-
40 min for GroEL/ES, and ~40-60 min for HSP60/10.  Next, the assays were quenched 
by addition of 10 µL of the EDTA stock, to final concentration of 100 mM.  Enzymatic 
activity of the refolded MDH was initiated by addition of 20 µL MDH enzymatic assay 
stock (20 mM sodium mesoxalate and 2.4 mM NADH in reaction buffer, 50 mM Tris pH 
7.4, 50 mM KCl, 1 mM DTT), and followed by measuring the NADH absorbance in each 
well at 340 nm using a Molecular Devices, SpectraMax Plus384 microplate reader 
(NADH absorbs at 340 nm, while NAD+ does not).  A340 nm measurements were recorded 
at 0.5 minutes (start point) and at successive time points until the amount of NADH 
consumed reached ~90% (end point, generally between 20-35 minutes).  The 
differences between the start and end point A340 values were used to calculate the % 
inhibition of the GroEL/ES or HSP60/10 machinery by the compounds.  IC50 values for 
the test compounds were obtained by plotting the % inhibition results in GraphPad Prism 
6 and analyzing by non-linear regression using the log (inhibitor) vs. response (variable 
slope) equation. Results presented represent the averages of IC50 values obtained from 
at least four replicates. 
Counter-screening compounds for inhibition of native MDH enzymatic activity. 
Reagent preparations and assay protocol:   
This assay was performed as described above for the GroEL/ES-dMDH refolding 
assay; however, the assay protocol differed in the sequence of compound addition to the 
assay plates. The refolding reactions were allowed to proceed for 45 min at 37°C in the 
absence of test compounds (complete refolding of MDH occurs), then quenched with the 
EDTA stock.  Compounds were then pin-transferred into the plates after the EDTA 
quenching step; thus, compounds effects are only possible by inhibiting the fully refolded 
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MDH reporter substrate.  Next enzymatic activity of the refolded MDH was initiated by 
addition of 20 µL MDH enzymatic assay stock (20 mM sodium mesoxalate and 2.4 mM 
NADH in reaction buffer, 50 mM Tris pH 7.4, 50 mM KCl, 1 mM DTT), and followed by 
measuring the NADH absorbance in each well at 340 nm using a Molecular Devices 
SpectraMax Plus384 microplate reader (NADH absorbs at 340 nm, while NAD+ does 
not).  A340 nm measurements were recorded at 0.5 minutes (start point) and at 
successive time points until the amount of NADH consumed reached ~90% (end point, 
generally between 20-35 minutes). Compounds were tested in 8-point, 3-fold dilution 
series (62.5 µM to 29 nM during the reporter reaction) in clear, flat-bottom 384-well 
microtiter plates.  DMSO was used as negative control, and previously discovered native 
MDH inhibitors were used as positive controls. IC50 values for the test compounds were 
obtained by plotting the % inhibition results in GraphPad Prism 6 and analyzing by non-
linear regression using the log (inhibitor) vs. response (variable slope) equation.  Results 
presented represent the averages of IC50 values obtained from at least four replicates. 
Evaluating compounds for inhibition in the GroEL/ES-dRho refolding assay. 
Reagent preparation:  
 For this assay, five primary reagent stocks were prepared: 1) GroEL/ES-dRho 
binary complex stock; 2) ATP initiation stock; 3) Enzyme solution; 4) Formaldehyde 
quench solution; 5) Fe(NO3)3 assay stock. Denatured Rho (dRho) was prepared by 3-
fold dilution of Rho (Roche product #R1756, stock diluted to 10 mg/ml with H2O) with 
denaturant buffer (12 M Urea, 50 mM Tris, pH 7.4, and 10 mM DTT). Rho was 
completely denatured by incubating at room temperature for 45 min. The binary complex 
solution was prepared by slowly adding the dRho stock to a stirring solution of 
concentrated GroEL in modified folding buffer (50 mM Tris-HCl, pH 7.4, 50 mM KCl, 10 
mM MgCl2, 5 mM Na2S2O3 and 1 mM DTT). The solution was centrifuged at 16,000 x g 
for 5 minutes, and the supernatant was collected and added to a solution of GroES in 
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modified folding buffer to give final protein concentrations of 100 nM GroEL, 120 nM 
GroES, and 80 nM dRho in modified folding buffer. The binary complex stock was 
prepared immediately prior to use. For the ATP initiation stock, ATP solid was diluted 
into modified folding buffer to a final concentration of 2.0 mM. The thiocyanate enzymatic 
assay stock was prepared to contain 70 mM KH2PO4, 80 mM KCN, and 80 mM Na2S2O3 
in water. The formaldehyde quench solution contained 30% formaldehyde in water. The 
ferric nitrate reporter stock contained 8.5% w/v Fe(NO3)3 and 11.3% v/v HNO3 in water. 
Assay protocol:  
 First, 10 mL aliquots of the GroEL/ES-dRho complex stock was dispensed into 
clear, 384-well polystyrene plates. Next, 0.5 mL of the compound stocks (10 mM to 4.6 
mM, 3-fold dilutions in DMSO) were added by pin-transfer. The chaperonin-mediated 
refolding cycle was initiated by addition of 10 mL of ATP stock (reagent concentrations 
during refolding cycle: 50 nM GroEL, 60 nM GroES, 40 nM dRho, 1 mM ATP, and 
compounds of 250 mM to 114 nM, 3-fold dilution series). After incubating for 45 minutes 
at 37°C for the refolding cycle, 30 mL of the thiocyanate enzymatic assay stock was 
added and incubated for 60 min at room temperature for the refolded rhodanese 
enzymatic reporter reaction. The rhodanese-catalyzed thiosulfate-cyanide reaction was 
quenched by adding 10 mL of the formaldehyde quench solution, and then 40 mL of the 
ferric nitrate reporter stock was added to quantify the amount of thiocyanate produced 
during the enzymatic reporter reaction, which is proportional to the amount of dRho 
refolded by GroEL/ES. After incubating at room temperature for 15 min, the absorbance 
by Fe(SCN)3 was measured at 460 nm using a Molecular Devices, SpectraMax Plus384 
microplate reader. A second set of baseline control plates were prepared analogously, 
but without binary solution, to correct for possible interference from compound 
absorbance or turbidity. IC50 values for the test compounds were obtained by plotting the 
A460 results in GraphPad Prism 6 and analyzing by non-linear regression using the 
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log(inhibitor) vs. response (variable slope) equation. Results presented represent the 
averages of IC50 values obtained from at least four replicates. 
Counter-screening compounds for inhibition of native Rho enzymatic activity. 
Reagent preparations and assay protocol:   
Reagents were identical to those used in the GroEL/ES-dRho refolding assay 
described above; however, the assay protocol differed in the sequence of compound 
addition to the wells. Compounds were pin-transferred after the 60-minute incubation for 
the refolding cycle, but prior to the addition of the thiocyanate enzymatic assay stock.  
Thus, the refolding reactions were allowed to proceed for 60 min at 37°C in the absence 
of test compounds, but the enzymatic activity of the refolded rhodanese reporter enzyme 
was monitored in the presence of test compounds (inhibitor concentration range during 
the enzymatic reporter reaction is 100 mM to 46 nM – 3-fold dilutions). IC50 values for 
the rhodanese reporter enzyme were determined as described above. Results presented 
represent the averages of IC50 values obtained from at least three replicates. 
Evaluating compounds for inhibition of M. smegmatis proliferation. 
Mycobacterium smegmatis – (Trevisan) Lehmann and Neumann strain (ATCC 
700084). M. smegmatis was grown in Middlebrook complete media (Becton, Dickinson 
and Company). The liquid culture was grown in Middlebrook complete media 
supplemented with 0.05% Tween 80. Stock bacterial cultures were streaked onto agar 
plates and grown for 72 h at 37°C.  Fresh aliquots of broth were inoculated with single 
bacterial colonies and the cultures were grown overnight at 37°C with shaking (240 rpm) 
in media. The following morning, the overnight cultures were sub-cultured (1:5 dilution) 
into fresh aliquots of media and grown at 37°C for 1-2 h with shaking. After 2 h, cultures 
were diluted into fresh media to achieve final OD600 readings of 0.05. Aliquots of these 
diluted cultures (20 µL) were added to clear, flat-bottom, 384-well polystyrene plates that 
were stamped with 1 µL of test compounds in 20 µL media. Compounds were tested in 
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dose-response format where the inhibitor concentration range during the proliferation 
assay was 100 µM to 46 nM (3-fold dilution series). Plates were sealed with "Breathe 
Easy" oxygen permeable membranes (Diversified Biotech) and left to incubate at 37°C 
without shaking (stagnant assay). A second set of baseline control plates were prepared 
analogously, but without any bacteria added, to correct for possible compound 
absorbance and/or precipitation. After 24 h, plates were then read at 600 nm using a 
Molecular Devices SpectraMax Plus384 microplate reader. EC50 values for the test 
compounds were obtained by plotting the OD600 results in GraphPad Prism 6 and 
analyzing by non-linear regression using the log(inhibitor) vs. response (variable slope) 
equation. Results presented represent the averages of EC50 values obtained from at 
least triplicate experiments. 
Evaluating compounds for inhibition of M. tuberculosis proliferation. 
 Evaluation of compound inhibition of M. tuberculosis proliferation in liquid culture 
was performed as per previously reported procedures (Ollinger 2013). M. tuberculosis  
(strain H37Rv) was grown in Middlebrook 7H9 medium supplemented with 0.05% Tween 
80, 10% v/v oleic acid, and albumin dextrose catalase (OADC) supplement (Becton 
Dickinson) (7H9-Tw-OADC). Stock bacterial cultures were inoculated in a startup culture 
and grown to a logarithmic phase of OD590 ~0.7.  This was sub-cultured in fresh media 
(1:10 dilution) and grown to an OD590 1.0, then diluted again into fresh media to achieve 
a final OD590 reading of 0.04 (just prior to dispensing into plates). Compound plates were 
prepared by adding 4 µL of compound stocks to 96 µL of fresh medium in 96-well plates.  
Aliquots of the diluted Mtb cultures (100 µL) were then added to the compound plates, 
which were incubated in sealed bags at 37ºC for 5 days.  All compounds were first 
evaluated in singlicate at a single concentration of 200 µM, with compounds showing 
>50% inhibition re-evaluated in dose-response format (inhibitor concentration range of 
200 µM to 390 nM – 2-fold dilutions) to determine EC50 values.  After 5 days, OD590 
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values were read and % growth inhibition for each well were calculated.  EC50 values for 
compounds tested in dose-response format were obtained by plotting the % inhibition 
results in GraphPad Prism 6 and analyzing by non-linear regression using the log 
(inhibitor) vs. response (variable slope) equation.  Results presented represent the 
averages of EC50 values obtained from duplicate experiments. 
Evaluating compounds for effects on liver and kidney cell viability.  
 Evaluation of compound cytotoxicity’s to THLE-3 liver and HEK 293 kidney cells 
was performed using Alamar Blue-based viability assays. THLE-3 cells were maintained 
in Clonetics BEBM medium (Lonza, CC-3171) supplemented with the BEGM bullet kit 
(Lonza, CC-3170) and 10% FBS. HEK 293 cells were maintained in MEM medium 
(Corning Cellgro, 10-009 CV) supplemented with 10% FBS (Sigma, F2242). All assays 
were carried out in 384-well plates (BRAND cell culture grade plates, 781980).  Cells at 
80% confluence were harvested and diluted in growth medium, then 45 µL of the THLE-
3 cells (1,500 cells/well) or HEK 293 cells (1,500 cells/well) were dispensed per well, and 
plates were sealed with "Breathe Easy" oxygen permeable membranes (Diversified 
Biotech) and incubated at 37°C, 5% CO2, for 24 h. The following day, 1 µL of the 
compound stocks (10 mM to 4.6 µM, 3-fold dilutions in DMSO) were pre-diluted by pin-
transfer into 25 µL of the relevant growth mediums. Then, 15 µL aliquots of the diluted 
compounds were added to the cell assay plates to give inhibitor concentration ranges of 
100 µM to 46 nM during the assay (final DMSO concentration of 0.1% was maintained 
during the assay). Plates were sealed with "Breathe Easy" oxygen permeable 
membranes and incubated for an additional 48 h at 37°C and 5% CO2. The Alamar Blue 
reporter reagents were then added to a final concentration of 10%, the plates incubated 
at 37°C and 5% CO2, and sample fluorescence (535 nm excitation, 590 nm emission) 
was read using a Molecular Devices FlexStation II 384-well plate reader (readings taken 
between 4-24 h of incubation so as to achieve signals in the 30-60% range for 
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conversion of resazurin to resorufin). Cell viability was calculated as per vendor 
instructions (Thermo Fisher - Alamar Blue cell viability assay manual). Cytotoxicity CC50 
values for the test compounds were obtained by plotting the % resazurin reduction 
results in GraphPad Prism 6 and analyzing by non-linear regression using the 
log(inhibitor) vs. response (variable slope) equation. Results presented represent the 
averages of CC50 values obtained from at least three replicates for THLE-3 liver cells 
and four replicates for HEK 293 kidney cells. 
Mtb PtpB & human PTPN1 (PTP1B), PTPN2 (TCPTP), and PTPN5 (STEP) protein 
expression and purification 
Mtb PtpB: 
 His-tagged Mycobacterium tuberculosis PtpB was expressed from a T7-
promoted (pET21b-PtpB) and ampicillin resistance plasmid in Rosetta™ 2 (DE3) E. coli 
cells. Transformed cells were grown at 37°C in LB / ampicillin / chloramphenicol medium 
until an OD600 of ~0.3 was reached, then were induced with 20 µM IPTG and incubated 
overnight at 20°C. The culture was centrifuged at 8,000 rpm, and the cell pellet was re-
suspended in Buffer A (20 mM Tris-Cl, pH 7.4, 200 mM NaCl, 10 mM Imidazole, and 5% 
glycerol) supplemented with EDTA-free complete protease inhibitor cocktail (Roche). 
The cells were lysed by sonication, centrifuged, and the clarified cell lysate was loaded 
on a nickel-agarose resin column. The His-tagged PtpB protein was eluted using a linear 
gradient of 100% Buffer A to 100% Buffer B (20 mM Tris-Cl, pH 7.4, 200 mM NaCl, 500 
mM Imidazole, 5% glycerol). Fractions containing the PtpB phosphatase were spin 
concentrated, then dialyzed (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM 
DTT, and 5% glycerol) using 10 kDa SnakeSkin™ dialysis tubing (Thermo Scientific). 
The concentration of protein was determined by Coomassie Protein Assay Kit (Thermo 
Scientific). Batches of protein were stored at 4°C in 20 mM Tris-Cl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1 mM DTT, and 20% glycerol for up to three weeks, then discarded.  
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Human PTPN1 (PTP1B), PTPN2 (TCPTP), and PTPN5 (STEP):  
 Each of the human phosphatases was expressed from T7-promoted (pSPEED-
ET) and kanamycin resistant plasmids in Rosetta™ 2 (DE3) E. coli cells. Transformed 
bacteria were grown at 37ºC in LB / kanamycin medium until an OD600 of ~0.3 was 
reached, then were induced with 20 µM IPTG and incubated overnight at 20°C. The 
cultures were centrifuged at 8,000 rpm, and the cell pellets were re-suspended in Buffer 
A (20 mM Tris-Cl, pH 7.4, 200 mM NaCl, 10 mM Imidazole, and 5% glycerol) 
supplemented with EDTA-free complete protease inhibitor cocktail (Roche). The cells 
were lysed by sonication, centrifuged, and the clarified cell lysates were loaded on a 
nickel-agarose resin column. The His-tagged proteins were eluted using linear gradients 
of 100% Buffer A to 100% Buffer B (20 mM Tris-Cl, pH 7.4, 200 mM NaCl, 500 mM 
Imidazole, 5% glycerol). Fractions containing the phosphatases were spin concentrated, 
then dialyzed with storage buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1 mM DTT, and 5% glycerol) using 10 kDa SnakeSkin™ dialysis tubing (Thermo 
Scientific). The concentration of each phosphatase was determined by Coomassie 
Protein Assay Kit (Thermo Scientific). Batches of the proteins were stored at 4°C in 20 
mM Tris-Cl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 5% glycerol for up to three 
weeks, then discarded.  
Evaluating compounds for inhibition of the Mtb PtpB and human phosphatases.  
Reagent preparation:  
 For these assays, three primary reagent stocks were prepared: 1) phosphatase 
enzyme solutions, containing M. tuberculosis PtpB or human PTPN1 (PTP1B), PTPN2 
(TCPTP), or PTPN5 (STEP); 2) pNPP solution; and 3) NaOH developing solution. The 
phosphatase enzyme solutions contained 50 nM of either of the four phosphatases in 
assay buffer (50 mM 3,3-dimethyl glutarate, pH 7.0, 150 mM NaCl, 1 mM EDTA, and 1 
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mM DTT).  The pNPP solution contained 4.16 mM of para-nitrophenyl phosphate in 
assay buffer.  The NaOH developing solution contained 6 M NaOH.  
General assay protocol:  
 First, 20 µL aliquots of the phosphatase enzyme solutions were dispensed into 
clear, 384-well polystyrene plates.  Next, 0.5 µL of the compound stocks (10 mM to 4.6 
µM, 3-fold dilutions series in DMSO) were added by pin-transfer.  The phosphatase 
enzymatic reactions were then initiated by addition of 30 µL of the pNPP solution.  The 
plates were incubated 37°C for either 30 min (Mtb PtpB) or 45 min (human 
phosphatases), then 10 µL of the NaOH developing solution was added.  The 
absorbance at 405 nm was measured in each well (monitoring for the phenolate product) 
using a Molecular Devices, SpectraMax Plus384 microplate reader.  A second set of 
baseline control plates were prepared analogously, but without any phosphatases 
present, to correct for possible interference from compound absorbance or turbidity.  IC50 
values for the test compounds were obtained by plotting the A405 results in GraphPad 
Prism 6 and analyzing by non-linear regression using the log(inhibitor) vs. response 
(variable slope) equation.  Results presented represent the averages of IC50 values 
obtained from at least six replicates for each phosphatase. 
Control compounds, calculation of IC50 values, and statistical considerations. 
 
For the chaperonin-mediated biochemical assays, DMSO was used as negative 
control, and a panel of our previously discovered and reported chaperonin inhibitors 
were used as positive controls: e.g. compounds 8, 9, and 18 from Johnson et. al 2014 
and Abdeen et. al 2016; suramin and compound 2h-p from Abdeen et. al 2016; 
compounds 20R, 20L, and 28R from Abdeen et. al 2018. All IC50 results reported are 
averages of values determined from individual dose-response curves in assay replicates 
as follows: 1) Individual IC50 values from assay replicates were first log-transformed and 
the average log(IC50) values and standard deviations (SD) calculated; 2) Replicate 
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log(IC50) values were evaluated for outliers using the ROUT method in GraphPad Prism 
6 (Q of 10%); and 3) Average IC50 values were then back-calculated from the average 
log(IC50) values. For compounds where log(IC50) values were greater than the maximum 
compound concentrations tested (i.e. >1.8, >2.0, and >2.4 – or >63, >100, and >250 
mM, respectively), results were represented as 0.1 log units higher than the maximum 
concentrations tested (i.e. 1.9, 2.1, and 2.5 – or 79, 126, and 316 mM, respectively) so 
as not to overly bias comparisons because of the unavailability of definitive values for 
these inactive compounds. 
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APPENDIX  
Table 5A – IC50 and EC50 biochemical assay results for analogs 1 and 2a-m. 
Compounds that were tested in the PTPN2 phosphatase assay for which their dose-
response curve baselines did not go to zero, but appeared to plateau between 10-30% 
inhibition, are labeled with a superscript “bp”. 
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Table 5B – Log(IC50 and EC50) biochemical assay results ± SD for analogs 1 and 2a-m. 
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Table 6A – EC50 and CC50 cell viability results for analogs 1 and 2a-m. 
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Table 6B – Log(EC50 and CC50) cell viability results ± SD for analogs 1 and 2a-m. 
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Table 7A – IC50 and EC50 biochemical assay results for analogs 2-14. Compounds that 
were tested in the PTPN2 phosphatase assay for which their dose-response curve 
baselines did not go to zero, but appeared to plateau between 10-30% inhibition, are 
labeled with a superscript “bp”. 
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Table 7B – Log(IC50 and EC50) biochemical assay results ± SD for analogs 2-14. 
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Table 8A – EC50 and CC50 cell viability results for analogs 2-14. 
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Table 8B – Log(EC50 and CC50) cell viability results ± SD for analogs 2-14. 
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Table 9A – IC50 and EC50 biochemical assay results for analogs 15 and 16R-34R. 
Compounds that were tested in the PTPN2 phosphatase assay for which their dose-
response curve baselines did not go to zero, but appeared to plateau between 10-30% 
inhibition, are labeled with a superscript “bp”. 
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Table 9B – Log(IC50 and EC50) biochemical assay results ± SD for analogs 15 and 16R-
34R. 
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Table 10A – EC50 and CC50 cell viability results for analogs 15 and 16R-34R. 
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Table 10B – Log(EC50 and CC50) cell viability results ± SD for analogs 15 and 16R-34R. 
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Table 11A – IC50 and EC50 biochemical assay results for analogs 15 and 16L-34L. 
Compounds that were tested in the PTPN2 phosphatase assay for which their dose-
response curve baselines did not go to zero, but appeared to plateau between 10-30% 
inhibition, are labeled with a superscript “bp”. 
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Table 11B – Log(IC50 and EC50) biochemical assay results ± SD for analogs 15 and 16L-
34L. 
 
 
 
  
	78 
Table 12A – EC50 and CC50 cell viability results for analogs 15 and 16L-34L. 
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Table 12B – Log(EC50 and CC50) cell viability results ± SD for analogs 15 and 16L-34L. 
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Table 13A – IC50 and EC50 biochemical assay results for analogs R35-R51.  Compounds 
that were tested in the Mtb PtpB phosphatase assay for which their dose-response 
curves first showed an activation, followed by inhibition of enzymatic activity at 
increasing compound concentrations are labeled with a superscript “AI”.  A superscript 
“A” indicates only activation was observed with increasing compound concentrations. 
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Table 13B – Log(IC50 and EC50) biochemical assay results ± SD for analogs R35-R51. 
 
 
 
  
	82 
Table 14A – EC50 and CC50 cell viability results for analogs R35-R51. 
 
 
 
  
	83 
Table 14B – Log(EC50 and CC50) cell viability results ± SD for analogs R35-R51. 
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Table 15A – IC50 and EC50 biochemical assay results for analogs L35-L51.  Compounds 
that were tested in the Mtb PtpB phosphatase assay for which their dose-response 
curves first showed an activation, followed by inhibition of enzymatic activity at 
increasing compound concentrations are labeled with a superscript “AI”.   
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Table 15B – Log(IC50 and EC50) biochemical assay results ± SD for analogs L35-L51. 
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Table 16A – EC50 and CC50 cell viability results for analogs L35-L51. 
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Table 16B – Log(EC50 and CC50) cell viability results ± SD for analogs L35-L51. 
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